

AUTHOR INDEX

A

Abbott TM, 1269
 Abo T, 623
 Abramson SB, 630
 Acton RT, 1412
 Adams ME, 69
 Aguado MT, 156
 Agudelo CA, 930, 1522
 Agus B, 237
 Ahearn JM, 1533
 Aisen PS, 1404
 Akizuki M, 604
 Alarcón GS, 238, 1412
 Alarcón-Segovia D, 688, 1266, 1535
 Alcocer-Varela J, 1266
 Aldo-Benson MA, 678, 928
 Allaire S, 658
 Allen JB, 560, 1076, 1259, 1442
 Almendinger R, 841
 Alonso JLG, 207
 Alspaugh MA, 712
 Alterescu V, 934
 Altman RD, 866
 Altz-Smith M, 1303
 Alvarellos A, 1533
 Alvarez JdeP, 207
 Alvarez-Arenas RP, 1175
 Amor B, 809, 935, 1416
 Andersen BR, 1160
 Andersen RB, 479
 Anderson JJ, 1017
 Anderson RB, 1166
 Andrews BS, 121
 Andrews P, 1427
 Ansher AF, 804
 Aoki Y, 1002
 Arenillas JIC, 207
 Arias M, 854
 Arnett FC, 1279, 1533
 Arroyo J, 784
 Arthur RE, 1499
 Arturi AS, 567
 Asherson RA, 1037
 Askari AD, 121
 Athreya BH, 728
 Auquier L, 1472
 Ayoub WT, 809

B

Badger H, 45
 Bahrt KM, 811
 Baker DG, 8
 Bakke AC, 745
 Bakshi A, 954
 Balch CM, 623

Baldassare AR, 1499
 Ball GV, 238
 Ballou SP, 1295
 Bankhurst AD, 1091, 1316, 1452
 Banks PM, 1201
 Barada FA Jr, 1
 Baraf HSB, 1057
 Barberis L, 1173
 Barger BO, 1412
 Barnard JM, 1011
 Barnes EL, 500
 Baron M, 969
 Barry M, 1041
 Bartleson JD, 201
 Baruth B, 532
 Batchelor JR, 102, 921
 Batstone GF, 1532
 Baum J, 599
 Beale MG, 1399
 Beardmore T, 494
 Becks E, 1460
 Bell CL, 801
 Bellamy N, 705
 Bellon EM, 226
 Bembe ML, 1
 Bene MC, 1173
 Benhamou L, 935, 1416
 Benlahrache C, 1472
 Bennett JC, 548
 Bennett RM, 817
 Benson CH, 696
 Benson MD, 1145, 1493
 Bergroth V, 1196
 Bernstein R, 1037
 Bertken R, 693
 Bias WB, 1533
 Bignall MC, 522
 Bijlsma A, 814
 Bilge N, 1052
 Billingham MEJ, 69
 Birchmore DA, 637
 Birdsall HH, 1481
 Black CM, 921
 Blank DW, 574
 Blatter D, 560
 Blechman WJ, 1413
 Blocka KL, 1303
 Bobrove AM, 118
 Bole GG, 617, 1033
 Bookman AAM, 106
 Borda IA, 1175
 Borden S IV, 728
 Boumphrey FRS, 77
 Bouvet J-P, 1472
 Boyce E, 1303
 Boyd RE, 637
 Boyle JA, 509
 Bradlow HL, 1517

Brandslund I, 721
 Brandt KD, 528, 771, 994, 1065, 1231
 Bridgeford PH, 925
 Brinckerhoff CE, 1370
 Britz ML, 984
 Bromley M, 1427
 Brooks PM, 705
 Broom ND, 1111
 Browning CP, 1044
 Brunner CM, 736
 Brunzell JD, 127
 Bryan WJ, 1140
 Buchanan RRC, 146
 Buchanan WW, 28
 Buckingham RB, 500
 Bunch TW, 806, 1529
 Burge JR, 645
 Burmester GR, 1187
 Burns T, 1460
 Burry HC, 98
 Buschbacher R, 736
 Butler M, 875, 1132, 1380

C

Cabral A, 1362
 Caglar MK, 1536
 Calabrese LH, 77
 Calandra GB, 560, 1442
 Caldwell JH, 1163
 Calhoon SL, 1275
 Calin A, 937, 1460
 Calin HJ, 937
 Calkins E, 576
 Calvano SE, 113
 Campbell IK, 984
 Campbell PM, 94
 Campbell SM, 817
 Campion EW, 87
 Cannon GW, 1269
 Cappellacci S, 1053
 Carette S, 186
 Carlin JS, 127
 Carpenter CB, 1104
 Carrera GF, 760
 Carter RL, 462
 Cartwright EC, 984
 Casanueva B, 854
 Castor CW, 522, 1362
 Cathcart ES, 581
 Ceuppens JL, 1419
 Chafetz NI, 1387
 Chalmers A, 574
 Chalmers IM, 1011
 Charles PJ, 146
 Chart J, 1132
 Cheng P-T, 682
 Chesney C, 45

Chiorazzi N, 39
 Christine TA, 764
 Chui DHK, 28
 Ciosek CP Jr, 15
 Clark S, 817
 Clarke BJ, 28
 Clegg DO, 1269
 Clemmensen I, 479
 Clements PJ, 961
 Cohen AS, 658
 Cohen E, 674
 Cohen MD, 201, 1201
 Cohen PL, 975
 Cohen S, 170
 Cohen Z, 106
 Colombo C, 875, 1132, 1380
 Colver G, 813
 Condemni JJ, 117
 Cook SA, 77
 Coombes EJ, 1532
 Cooney L, 1041
 Cooperman L, 694
 Costello PB, 541
 Coulie PG, 1085
 Craig CA, 692
 Craig R, 238
 Creager MA, 1177
 Croft SM, 238
 Cronstein BN, 1404
 Crowe WE, 214

D

Damteu B, 217
 Dard S, 816
 Davis DE, 1291
 Davis JS I', 1098
 Davis P, 82, 914
 Dawes PT, 695
 Dayer E, 156
 Dayer J-M, 8
 Decaux G, 1055
 Decker JL, 1029, 1076
 Deicher H, 532
 De León C, 1292
 Del Paine DW, 691
 de Merieux P, 961
 De Pita O, 1294
 Dequeker J, 1419
 DeSimone DP, 1245
 Destouet JM, 1150
 Devereaux MD, 236
 Díaz de Rojas F, 1175
 Diaz-Jouanan E, 1535
 Dinarello CA, 975
 Dixon FJ, 1340
 Dobloug JH, 35
 Dorner RW, 165, 653
 Dorsch CA, 179, 1533

Dorwart BB, 1166
 Dougados M, 935, 1416
 Doury P, 689
 Doyle D, 813
 Dubo HIC, 751
 Dumas J-M, 109
 Durham JB, 645
 Dwulet FE, 1493

E

Eaton RB, 52
 Ebbs S, 813
 Edelson HS, 630
 Edelstein G, 1511
 Egan ML, 623
 Egger MJ, 581, 1303
 Ehresmann GR, 745
 Ehrlich GE, 240
 Elkon KB, 102, 921
 Emmons RP, 1098
 Engelbrecht JA, 1275
 Engleman EG, 937
 Englert ME, 1120
 Enis JE, 63
 Epstein WV, 901
 Esdaile J, 217
 Espinoza LR, 925
 Eulry F, 689
 Evers AE, 1071
 Eversmeyer WH, 932
 Eyanson S, 1145

F

Fairbanks VF, 806
 Fallet GH, 784
 Falus A, 721
 Fam AG, 1525
 Faure G, 1173
 Feiglin D, 969
 Ferguson RK, 791
 Fernandes G, 113
 Fernández del Vallado P, 1292
 Ferrell LD, 1387
 Fidler WJ, 1214
 Fiechtner JJ, 127
 Field EH, 937
 Fife RS, 928
 Fink CW, 896
 Finnie S, 462
 Forehand ME, 817
 Førrø O, 35
 Forrester DM, 664
 Forsum U, 1321, 1333
 Fotino M, 210
 Francis MD, 861
 Freemont AJ, 1427
 Friede RL, 825
 Friedman JM, 214

Fries JF, 697, 1055
 Friman C, 231
 Fritzler MJ, 140, 914
 Froelich CJ, 1452
 From A, 234
 Fujita T, 472
 Furst DE, 581

G

Galeazzi M, 1053, 1294, 1499
 Galiana JR, 1175
 Gallis HA, 1044
 García MC, 1175
 García-Fuentes M, 854
 García-Morteo O, 567, 815, 936
 Garfin SR, 240
 Gautama K, 1419
 Gay RE, 1231
 Gay S, 1231
 Geiseler PJ, 1160
 Genant HK, 1387
 George D, 674
 Germain BF, 925
 Gerster JC, 156
 Gertner E, 1525
 Getz HD, 728
 Gewanter HL, 599
 Ghandur-Mnaymeh L, 63, 866
 Gibofsky A, 39, 120, 210
 Gibson JY, 696
 Gigli I, 210
 Gillings DB, 1354
 Ginsberg MH, 775
 Ginsburg WW, 201, 1201
 Gittelsohn AM, 1465
 Given WP, 630
 Gladman DD, 1181
 Glynn RJ, 87
 Goffin YA, 120
 Goldbach P, 221
 Goldberg J, 1412
 Goldenberg DL, 658
 Goldfarb PM Jr, 238
 Golds EE, 15
 Goldsmith DP, 668
 González-Amaro RF, 688
 Good RA, 113
 Goode E, 106
 Goodwin JS, 486
 Gordo JMA, 1175
 Górriz L, 1292
 Graham D, 186
 Grandone JT, 581
 Graziano FM, 801
 Green FA, 541
 Groff GD, 119
 Gutierrez DA, 207
 Guttadauria M, 581, 1303

H

Haber G, 811
 Hadler NM, 1354
 Hahn BH, 692, 1399
 Halla JT, 581
 Halverson PB, 1220
 Hamilton JA, 15
 H'ang L, 1340
 Hanson V, 214
 Harcup C, 1409
 Harisdangkul V, 696
 Harrelson JM, 1044
 Harrington TM, 201, 809, 1291
 Harris M, 797
 Harvey AR, 28
 Haslock I, 695
 Hassink SG, 668
 Hayes SP, 1303
 Hazelton RA, 236
 Healey LA, 930, 1417
 Hedfors E, 1321, 1333
 Helliwell M, 1532
 Henry JP, 1340
 Herrero-Beaumont G, 1292
 Hess CE, 736
 Hess E, 1536
 Hickman L, 875, 1132, 1380
 Hillman KS, 1023
 Hirohata K, 1434
 Hirszel P, 1056
 Hoagland HC, 806
 Hoch S, 674
 Hochberg MC, 1465
 Hoffman RG, 760
 Hoffman RW, 645
 Hollingworth P, 98
 Holmes EW, 1057
 Holt D, 1522
 Hølund B, 479
 Homma M, 604
 Hooks JJ, 575
 Hoppe RT, 937
 Horgan C, 736
 Horn PA, 861
 Horwitz DA, 745
 Hoskins LC, 121
 Hossler PA, 522
 Howell DS, 63, 866
 Høyeraal HM, 35
 Huffstutter EH, 832
 Hughes GRV, 102, 921
 Hughes JA, 1054
 Hummon NP, 1346
 Hunder GG, 1201
 Hunter T, 751
 Hurd E, 170
 Hurwitz S, 210
 Husby G, 1155
 Hyland R, 969

I

Ihrle EJ, 975
 Imura H, 118
 Inada S, 604
 Inglis AE, 1140
 Ishibashi Y, 612
 Ishikawa H, 1434
 Iwase R, 896

J

Jablonska S, 617
 Jacobs P, 814
 Jacobs RP, 1245
 Jacobsen IA, 234
 Jaffee I, 593
 Jakle C, 691
 James KK, 45
 Jarrett MP, 238
 Johansson E, 231
 Johnson AM, 121
 Johnson AR, 170
 Johnson KE, 1245
 Johnston C, 82
 Jones CJP, 1427
 Jones JV, 45
 Jonsson R, 1506

K

Kahan A, 809
 Kaiser DL, 637
 Kandel RA, 682
 Kang AH, 22, 832, 1237
 Kantrowitz F, 674
 Kaplan D, 239
 Kaplan HS, 937
 Kaplan SB, 581, 1303
 Karsh J, 109
 Katona IM, 1076
 Katz L, 1041
 Katz P, 462
 Kaufman RL, 494
 Kazis LE, 1017
 Kean WF, 28, 705
 Kenouch S, 816
 Kerwar SS, 1120
 Khan MA, 226
 Khoury MI, 1176
 Killmayer J, 179
 Kilpi A, 1196
 Kinay M, 1052
 Kinsella TD, 140
 Kirkland PA, 745
 Kitridou RC, 745
 Klareskog L, 1321, 1333
 Klein M, 1187
 Klippel J, 1303
 Knapp MJ, 1057
 Koike T, 570, 688

Kontinen YT, 231, 1196
 Koopman WJ, 1412
 Kotzin BL, 937
 Kovarsky J, 918, 1412
 Kowsari B, 462
 Kozin F, 760, 775
 Kramer JS, 901
 Kramer SB, 1404
 Krane SM, 8
 Kumagai Y, 841
 Kunkel HG, 39, 1517

L

Laffón A, 1266
 Lahita RG, 39, 1517
 Lally EV, 1283
 Lambert PH, 156
 Lampman JH, 1295
 Landes MJ, 1120
 Larsen B, 1011
 Larson EB, 94
 Larson MG, 570
 Leary SL, 815
 Leddy JP, 117
 Leek JC, 691
 Leff RD, 678, 928
 Lehman TJA, 1259
 Lehr JR, 1220
 Levinson JE, 214
 Levy JA, 1532
 Lewis A, 1525
 Liang MH, 570
 Lidsky MD, 1481
 Lightfoot RW Jr, 760
 Likar L, 1316
 Lindahl G, 1333
 Lindblad S, 1321, 1333
 Lindvall A-M, 1506
 Little H, 186
 Lloyd JM, 1120
 Lochead JA, 1011
 Lockshin MD, 210
 Lokaj J, 932
 Longley S, 462
 Lopez-Acuna D, 1465
 Lowenstein MB, 925
 Lowther DA, 984
 Lukáč J, 932
 Lulli P, 1053
 Luzar MJ, 1163
 Lynch MP, 564

M

Machinami R, 1002
 Machtley I, 933
 Mackenzie AH, 119
 Madura JA, 678
 Maini RN, 146
 Makinen D, 914

Malaviya AN, 1175
 Maldonado-Cocco JA, 567, 815, 936
 Mankin HJ, 1225
 Manu P, 1054
 Marcos JC, 567
 Marcus RW, 935
 Marder A, 1460
 Maricq HR, 617, 1169
 Marie PJ, 887
 Mark DA, 113
 Marshall WH, 1011
 Martel-Pelletier J, 63, 866
 Martini A, 1173
 Maryjowski ML, 214
 Masi AT, 812
 Mason JH, 577
 Maurer KH, 572
 Maury CPJ, 1196
 Mayer ME, 1160
 McCarty DJ, 564, 1220
 McCarty GA, 1, 140
 McCreary LD, 861
 McDonald MI, 1044
 McGrath M, 237
 McLoughlin MJ, 106
 McReynolds RA, 1120
 Meenan RF, 577, 658, 1017, 1303
 Mehra NK, 1175
 Mehran KG, 682
 Mehta K, 918
 Mekhjian H, 1163
 Melton JW III, 804
 Menche D, 1187
 Mendelsohn SL, 623
 Menkes CH, 809
 Merino J, 854
 Merryman P, 593, 1187
 Méry J-P, 816
 Meyer M, 825
 Michet CJ Jr, 1208
 Mieke H, 532
 Miller CL, 82
 Miller KB, 1177
 Miller MH, 1181
 Mimori T, 604
 Miyasaka N, 954
 Mohsenifar Z, 221
 Mongan ES, 494
 Moody BJ, 1532
 Moore JO, 1044
 Moore TL, 165, 557
 Morellini M, 1053
 Moretta L, 1098
 Morgenstern H, 933
 Moroi Y, 612
 Morrow WJW, 1532
 Mort JS, 887
 Mountz J, 1522
 Moutsopoulos HM, 575
 Muir H, 69

Mumford PA, 146
 Munves EF, 848
 Murphy WA, 1150, 1511
 Myers SL, 764

N

Nahoul K, 935
 Nakabayashi Y, 612
 Nanji AA, 574
 Nashel DJ, 811
 Nawata Y, 688
 Nayar S, 237
 Neiderhiser DH, 121
 Nelson AM, 1208
 Newell S, 1023
 Niebel JP, 1160
 Niederman JC, 553
 Niho Y, 516
 Nonoyama M, 712
 Norcross WA, 1296
 Norman ME, 728
 Notarangelo LD, 1173
 Notis WM, 690
 Nussbaum AI, 1169
 Nyberg G, 1506

O

Oakley CM, 1037
 O'Brien WM, 736
 O'Byrne E, 875, 1380
 Ochi T, 896
 Ocken S, 794
 O'Dell JR, 1413
 O'Fallon WM, 1208
 Okabe N, 896
 Okudaira K, 486
 Oliver JMT, 1175
 Ono K, 896
 Oronsky AL, 1120
 Osborn TG, 653
 Osial TA Jr, 500
 Østensen M, 1155

P-Q

Pachman LM, 214, 1536
 Palferman T, 813
 Palmoski MJ, 528, 771, 994, 1231
 Panush RS, 462
 Paquin JD, 217, 887
 Panu KM, 1177
 Park CH, 1295
 Parsons DB, 1245
 Patel DJ, 237
 Patel NJ, 557
 Pattin S, 689
 Paul H, 191

Paulus HE, 206, 961, 1288, 1397
 Paunicka K, 797
 Payne RH, 1011
 Pedersen PC, 234
 Peebles CL, 210
 Pelletier J-P, 63, 866
 Pennebaker J, 509
 Perlman SG, 238
 Permin H, 721
 Perruquet JL, 1291
 Pharriss BB, 694
 Pidoux I, 887
 Pierce JM, 500
 Pifer DD, 45
 Pinals RS, 812, 1214
 Pincus T, 1346
 Piper A, 1409
 Pisko EJ, 930
 Plebani A, 1173
 Pletscher LS, 692, 1399
 Plotz PH, 581, 1259
 Poole AR, 887
 Poole CA, 1111
 Pope R, 954
 Posada de la Paz M, 1175
 Postlethwaite AE, 22
 Prakash S, 1175
 Price JH, 1023
 Prickett JD, 133
 Prinz WA, 1091
 Pritzker KPH, 682
 Provost TT, 1279, 1533
 Quintavalla J, 1380
 Quismorio FP Jr, 494, 745

R

Radvany RM, 214
 Raman D, 695
 Ramos-Niembro F, 688
 Rapley WA, 682
 Ranawat CS, 1140
 Raskin NH, 791
 Rea T, 745
 Reading JC, 581, 1303
 Rees AJ, 102
 Reginato AJ, 191
 Rehm-Graves S, 77
 Reichlin M, 1279
 Reinitz E, 794
 Reitamo S, 231, 1196
 Renlund RC, 682
 Resnick D, 908
 Reynolds MD, 1415
 Reynolds PP, 1057
 Riccardi VM, 574
 Rice JR, 1
 Richardson BC, 1387
 Robbins DL, 691

Roberts DJ, 522
 Roberts RD, 1048
 Robinson DR, 133
 Rodnan GP, 500, 617, 841
 Rodriguez MA, 1091
 Rodriguez-Valverde V, 854
 Roelke M, 8
 Rogers JR, 1499
 Roghmann KJ, 599
 Romanoff NR, 690
 Room GRW, 146
 Rosen P, 186
 Rosenbloom AL, 931
 Rosenthal J, 1065
 Rosenthal L, 217
 Rosner F, 236
 Ross SC, 653
 Rossen RD, 1481
 Rothschild BM, 45, 816
 Roughley PJ, 887
 Roumm AD, 841
 Rovenský J, 932
 Rozboril MB, 617
 Rozkovec A, 1037
 Rubenstein J, 186
 Ruffelli M, 1294
 Runge LA, 695
 Ryan LM, 564, 760
 Ryan JP, 140
 Rynes RI, 921

S

Salem DN, 1177
 Salick AI, 221
 Samuelson CO Jr, 581, 1269, 1303
 Sánchez MC, 207
 Sandy JD, 984
 Sarti P, 1294
 Sauvezie B, 954
 Savage SM, 486
 Sawada K, 118
 Schattner A, 1415
 Scher I, 1076
 Scherbel AL, 119
 Scherrer JJ, 1275
 Schiavetti L, 1053
 Schlumpf U, 825
 Schneider S, 1409
 Schneider G, 52
 Schrieber L, 146
 Schroeder JL, 1399
 Schumacher HR, 8, 191, 728
 Schur PH, 52, 848, 1104
 Scott JT, 98
 Seaman W, 954
 Searles RP, 486
 Segond P, 1472
 Selwyn M, 875, 1132
 Sessoms S, 918
 Shapiro LS, 690

Sheridan PW, 165
 Sherlock S, 914
 Shiff B, 969
 Shiozawa K, 472
 Shiozawa S, 472
 Shirane H, 1434
 Shoji H, 712
 Sibbitt WL Jr, 1091, 1316, 1452
 Sigal LH, 553
 Silbert JE, 87
 Silver RM, 1169
 Simkin PA, 94, 127
 Singh G, 500
 Skanes VM, 1011
 Skillrud DM, 1529
 Slama TG, 1065
 Sliwinski AJ, 804
 Smith CA, 1214
 Smith HR, 1293
 Smith RD, 934
 Solomon SD, 572
 Solsky MA, 1303
 Somerfield SD, 235
 Soraci SA Jr, 1346
 Sorensen LB, 797
 Spellman CW, 1316
 Spencer CH, 214
 Starklint H, 234
 Steele R, 1380
 Steere AC, 553
 Steinberg AD, 133, 575, 1293
 Steinberg EB, 1293
 Steinetz B, 875, 1132, 1380
 Steinsson K, 1056
 Stephens-Larson P, 1340
 Stern M, 1499
 Stevens E, 1419
 Stevens M, 1085
 Stevens MB, 1533
 Strand V, 954
 Strober S, 937
 Strom J, 794
 Stross JK, 1033
 Stuart JM, 832, 1237
 Suchman AL, 117
 Sudell W, 1054
 Sueishi M, 570, 688
 Sugai M, 1525
 Sullivan JM, 581
 Summey JA, 1346
 Sundström C, 1321
 Sundstrom WR, 1071
 Sutherland DC, 102
 Svehag S-E, 721
 Swanson BN, 791
 Swartzendruber D, 875

T

Takehara K, 612
 Talal N, 954

Tamisier JN, 1173
 Tanay AS, 937
 Taswell HF, 806
 Taurog JD, 815
 Taylor RP, 736
 Taylor TH, 119
 Tenner AJ, 775
 Terkeltaub R, 775
 Terrell CP, 937
 Teshima R, 1225
 Tesser JRP, 1522
 Thabaut A, 689
 The HSG, 814
 Theil GB, 1048
 Thomas FB, 1163
 Thomas P, 1173
 Thompson LD, 45
 Thomsen BS, 234
 Thorsby E, 35
 Tindall EA, 817
 Tolvanen E, 231
 Tomada K, 1237
 Tomioka H, 570, 688
 Toral ME, 1023
 Torretti D, 809
 Továrek J, 932
 Towner SR, 1208
 Townes AS, 832, 1237
 Trahan CA, 1225
 Treadwell BV, 1225
 Turner RA, 1522
 Tuzi T, 1053, 1294

U-V

Ueno Y, 118
 Ugai K, 1434
 Ulrich J, 825
 Unger J, 1055
 Urowitz MB, 969, 1181
 van der Rest M, 887
 Van Snick JL, 1085
 Vasey FB, 925
 Venables PJW, 146
 Verdickt W, 1419
 Verity MA, 961
 Vermeylen C, 1419
 Versteeg CW, 814
 Vischer TL, 784
 Vojtková J, 932

W

Waggie KS, 645
 Wahl LM, 1076, 1442
 Wahl SM, 1076, 1442
 Walker SE, 645
 Wall BA, 930, 1522
 Wallston KA, 1346
 Walport MJ, 921
 Wanebo HJ, 736
 Ward JR, 581, 1269, 1303

Warszawski R, 217
 Watson MA, 581
 Weber S, 809
 Wegelius O, 1196
 Weinblatt M, 674
 Weinstein A, 581, 1056, 1303
 Weinstein AJ, 77
 Weiss JJ, 573
 Weiss TD, 557, 1499
 Weissbarth E, 532
 Weissmann G, 630, 1297
 Wernick R, 593
 West BC, 1292
 Wheat LJ, 1065
 Whiteside TL, 500, 841
 Wiik A, 721
 Wilder RL, 560, 1076, 1259, 1442
 Wilke WS, 119
 Williams HJ, 581, 1303
 Williams RC Jr, 1091
 Williamson GG, 509
 Willkens RF, 127, 1303
 Wilske KR, 930
 Wilson FJ, 1120
 Wilson HA, 121
 Winchester RJ, 39, 1187
 Winfield JB, 577
 Wing EJ, 1409
 Winston EL, 1177
 Wisner D, 127
 Witzleben CL, 728
 Woessner JF Jr, 63, 866
 Wolf BA, 791
 Wong K, 82
 Wong SW, 1048
 Wood DD, 975
 Wright I, 813

Y-Z

Yagan R, 226
 Yamagata H, 604
 Yamasake K, 516
 Yanase T, 516
 Yang HK, 645
 Yazici H, 1052
 Yeadon C, 109
 Yelin EH, 901
 Yi T, 146
 Yokoyama N, 1380
 Yoo TJ, 1237
 Yoshida S, 604
 Young AC, 637
 Yue CC, 1295
 Zeller J, 532
 Ziff M, 457, 593
 Zitnan D, 932
 Zuckner J, 165, 557, 653, 1499
 Zulman JJ, 1387
 Zyskowski LP, 806

SUBJECT INDEX

Arthritis and Rheumatism, Volume 26, Numbers 1 through 12, 1983

A

- Acanthocytosis, in McLeod syndrome, 806
- Acetabulum, protrusion of, 1511
- Acetylsalicylic acid. *See also* Aspirin; Salicylates
 - articular cartilage, collagen synthesis and, 1232
- Acetylthiocholine, 543
- Acidic nuclear protein antigen, in connective tissue disease, 604
- Acro necrosis, acquired, acroosteolysis and, 1150
- Acroosteolysis, acquired, acro necrosis and, 1150
- Activities of daily living, patient satisfaction in, 1346
- Acute oliguric tubulointerstitial nephropathy, 234
- Adenosine deaminase, 267
- Adherent cells, natural killing activity and, in Sjögren's syndrome, 954
- Adipose cells, fat necrosis and, in pancreatitis, 121
- Adjuvant arthritis, 251, 259
 - susceptibility of F344 rats to, 815
 - topical drugs in, 861
- Adult respiratory distress syndrome in SLE, 630
- Adult Still's disease, synovial microvasculature in, 1427
- Affinity purified antigens in detection of anti-SS-B antibodies, 146
- Affinity-purified anticollagen immunoglobulin in type II collagen-induced arthritis, 1120
- Age
 - CPPD deposition and, 1387
 - inorganic pyrophosphates in blood platelets and, 564
 - SLE and, 45
- Aggregate IgG-induced serotonin release, DNA and, 179
- ALA. *See* Antilymphocyte antibodies
- Albumin
 - cytotoxicity in scleroderma and, 170
 - in pancreatic arthritis, 127
 - plasma protein binding and, 775
 - in RA, 587
- Albumin binding sites in pancreatic arthritis, 127
- Albumin levels in RA, 1533
- Alcohol ingestion
 - hereditary chondrocalcinosis and, 1389
 - hyperuricemia and, in gout, 1057
- Algestone acetone, 1382
- Alizarin red S staining to detect calcium in synovial fluid, 191
- Alkaline phosphatase, intestinal isoenzyme of in RA, 574
- Allogeneic leukocytes in RA, after total lymphoid irradiation, 937
- Allopurinol, in gout, 277
- α Leu antibodies
 - identification of rheumatoid nodule cells by, 1333
 - in synovitis, 1321
- All-trans-retinoic acid, synovial fibroblast proliferation and, 1374
- Alternate complement pathway (AP50), immune complexes and, 156
- Ambulatory care rheumatology training, 658
- American Rheumatism Association
 - abstracts for annual meeting, 549
 - annual meeting, evaluation of, 577
 - Cooperating Clinic gold therapy trial, 1311
 - criteria for diagnosis of RA
 - in drug trials, 1355
 - polymyalgia rheumatica and, 1417
 - FDA Arthritis Advisory Committee Meeting, 206, 1288, 1397
 - Nomenclature and Classification of Arthritis and Rheumatism, 1029
 - Preliminary Criteria for Clinical Remission for Rheumatoid Arthritis, 812
 - Presidential Address, 548, 1297
 - 1982 Revised Criteria for Classification of SLE, 1054
- American rheumatology, 548
- Amino acids
 - CTAP and, 527
 - in sacroiliac and knee cartilage, 891
- Amino-phenylmercuric acetate in human OA cartilage, 63
- Amstat, 1380
- Amyloid. *See also* Amyloidosis
 - deposits
 - hereditary amyloidosis and, 1145
 - OA and, 120
 - heredofamilial, 332
- Amyloid tissue, serum amyloid P component and, 333
- Amyloidosis, 330
 - hereditary, 1145
 - Indiana type, 1493
 - secondary, diagnosis by endometrial biopsy, 1295
- Amyotrophic lateral sclerosis, creatine kinase in, 201
- Anarthritoid rheumatoid syndrome, 1417
- Androgen plasma, in females with RA, 935
- Androgens, role in behavior, 1520
- Androstenedione, in testosterone metabolism, 1518
- Anemia
 - in gout, 1057

Anemia (*cont'd*)

- hemolytic, anti-proliferating cell nuclear antigen and, 140
- naproxen and, 1054
- in histoplasmosis, 1065
- in RA, 28

Energy reversal, leukapheresis in RA and, 1076

Aneurysms, ruptured intrahepatic in polyarteritis nodosa, 106

Angiography in polyarteritis nodosa with ruptured hepatic aneurysm, 107

Animal models

- of arthritis, 253
- of OA, 69, 280
- of SLE, 310
- streptococcal cell wall-induced polyarthritis, 1442

Anionic polypeptides, binding by MSU crystals, 775

Ankle arthrocentesis

anterior tibial nerve palsy after, 573

Ankle surgery, 364

Ankylosing spondylitis, 323

antikeratin antibodies in, 494

in cervical spine, 226

genetic studies in, 1460

HLA-B27 in, 1011, 1460

natural course of, 186

nephropathy in, 816, 930

pelvis in, 229

pregnancy and, 1155

protrusio acetabuli in, 1513

Reiter's syndrome and, 1463

renal disease and, 930

spinal fractures complicating, 751

synovial fluid lactic acid in, 1500

synovial microvasculature in, 1427

^{99m}technetium methylene diphosphonate in, 217

Ankylosis, vertebral, in hereditary chondrocalcinosis (correction), 112

Antacids and esophageal abnormalities in polymyositis and dermatomyositis, 961

Anterior tibial nerve palsy after ankle arthrocentesis, 573

Anti-beta-2-microglobulin antibodies in Felty's syndrome, 721

Anti-beta-2-microglobulin autoantibodies, 721

Antibiotics in *Kingella kingae* infectious arthritis, 557

Antibodies

against proliferating cell nuclear antigen, 140

against RNP particles, 509

anti-beta-2-microglobulin, 721

anticentromere, 1, 914

anticollagen, 832

anti-Fab', 1481

anti-HLA-DR, 1333

anti-Ia, 486

anti-Jo-1, 604

anti-La, 509

antilymphocyte, 487, 954, 1456, 1535

Antibodies (*cont'd*)

antilymphocytotoxic, 570

anti-native DNA, 133

antinuclear, 1, 45, 612, 728, 944, 1104

anti-OKT, 486

anti-RNP, 509

anti-Ro (SSA), 509, 1279

anti-Sm, 509

anti-SS-A, anti-SS-B, 210

anti-(U1)-RNP, 509

beta-2-microglobulin, 721

in chronic liver diseases, 916

to collagen in rheumatic diseases, 832

Epstein-Barr virus, 554

identification of cells by, 1323

monoclonal, 486, 623, 745, 1173, 1187, 1196

to native DNA, 52

OKT, 745, 1196

RNP, 509, 848

in serum transfer of collagen-induced arthritis, 1237

SSA, 1279

Antibody/³H-dsDNA immune complexes, 736

Anticentromere antibodies

in CREST syndrome, 1

in primary biliary cirrhosis, 914

Anticollagen antibodies, 832, 1120

Anti-complement, neutrophil aggregation in SLE and, 630, 632

Antidiuretic hormone in SLE, 237, 1055

Anti-DNA antibodies, enzyme immunoassay and, in SLE, 52

Anti-estrogens in rabbit OA, 1132

Anti-Fab' antibodies in RA, 1481

Antigens

affinity purified, 146

Epstein-Barr virus, 712

HLA. *See* HLA antigens

nuclear, anti-proliferating cell, 140

nuclear protein, acidic, 604

OKT3, 623

rheumatoid arthritis nuclear (RANA), 712

smooth muscle, 494

soluble, lymphocyte tritiated thymidine incorporation in RA and, 1076

surface, 1196

Antigen-stimulated mononuclear leukocytes, fibroblast proliferation and, 22

Anti-HLA-DR antibodies for identification

of rheumatoid nodule cells, 1333

of synovial tissue cells, 1321

Anti-Ia antibodies, in RA, 486

Antiinflammatory drugs in RA, 345

Anti-Jo antibodies, in connective tissue diseases, 604

Anti-La antibodies, in rheumatic diseases, 509

Antilymphocyte antibodies

Ia specific, in RA, 486

Antilymphocyte antibodies (*cont'd*)

- in MCTD, 1535
- natural killing activity and
 - in Sjögren's syndrome, 954
 - in SLE, 1456
- Antilymphocytotoxic antibodies in SLE and MCTD, 570
- Antimalarial drugs, 356
- Anti-native DNA antibodies in autoimmune nephritis of mice, 133
- Anti-native DNA enzyme immunoassay in SLE and, 53
- Antinuclear antibodies
 - HLA haplotypes and, in SLE, 1104
 - Lowe's (oculocerebrorenal) syndrome and, 728
 - morphea and, 612
 - in RA, total lymphoid irradiation and, 944
 - in scleroderma, 1
 - localized, 612
- Anti-OKT monoclonal antibodies, in RA, 486
- Anti-proliferating cell nuclear antigens, 140
- Anti-RANA, in RA, 712
- Antirheumatic drugs, in rabbit model of OA, 1132
- Antirheumatoid arthritis antigen, clinical value of, 235
- Anti-RNP antibodies, 509
- Anti-Ro (SSA) antibodies
 - in rheumatic diseases, 509
 - in systemic lupus-like disease, 1279
- Anti-Sm antibodies, in rheumatic diseases, 509, 848
- Anti-SS-A antibodies
 - in neonatal lupus erythematosus, 210
 - in Sjögren's syndrome with scleroderma, 500
- Anti-SS-B antibodies. *See also* SS-B antibodies
 - binding of, 152
 - detection of by ELISA and Farr assays, 146
 - isotypes, 150
 - in neonatal lupus erythematosus, 210
 - in Sjögren's syndrome in scleroderma, 500
- Anti-type II collagen antibodies, collagen-induced arthritis and, 1237
- Anti-(U1)-RNP antibodies, in rheumatic diseases, 509
- Anturan, 1341
- Apatite crystal deposition disease
 - osteitis condensans ilii in, 567
 - staining for calcium in, 191
- Apatite crystals in synovial fluid, 191, 1220
- Aprotinin, 1382
- Arachidonic acid in autoimmune nephritis of mice, 137
- Arachidonic acid metabolism, nordihydroguaiaretic acid and, 771
- Aristospan, 1382
- Arterial involvement in scleroderma, 1042
- Arteritic lesions, in giant cell arteritis, 1201
- Arteritis. *See* Giant cell arteritis; Polyarteritis; Takayasu's arteritis
- Arthralgia in histoplasmosis epidemic, 1065
- Arthritis. *See also* Osteoarthritis; Polyarthritis; Soft tissue rheumatism

Arthritis (*cont'd*)

- Adjuvant, 251, 259, 815, 861
 - bacterial. *See* Infectious arthritis
 - in β -thalassemia minor, 1292
 - bypass, post intestinal and, 678
 - causes of, as perceived by public, 1027
 - classification of, 604, 1029
 - collagen-induced, 259, 1120, 1237, 1245
 - education of public on, 1023
 - enteric, 328, 1163
 - erosive, 1145
 - experimental models of, 253
 - fungal, 265
 - gonococcal, 263
 - gouty, 1057
 - gram-negative, 264
 - in histoplasmosis epidemic, 1065
 - infectious, 261, 557, 1166
 - inflammatory, 1145
 - inflammatory bowel disease and, 328
 - interleukin-1 in, 975
 - juvenile. *See* Juvenile arthritis
 - Lyme, 265
 - monarticular, acute, 236
 - monocytic, chronic, 674
 - mycobacterial, 265
 - neonatal onset multisystem inflammatory disease and, 668
 - pancreatic, 127
 - parasitic, 265
 - post intestinal bypass, 678
 - psoriatic, 328, 1156
 - public perceptions and misperceptions of, 1017
 - rheumatoid. *See* Rheumatoid arthritis
 - septic, 262, 1044
 - seronegative, 140
 - in SLE, 745, 1506
 - syphilitic, 265
 - traumatic, 975, 1187
 - unproven treatments in, 1023
 - viral, 264
- Arthritis and Rheumatism*, 548
- Arthritis Foundation
 - American Rheumatism Association and, 548
 - research funds, 551
- Arthritis Impact Measurement Scales, 1017
- Arthrocentesis, ankle, anterior tibial nerve palsy after, 573
- Arthrokadadysis, 1511
- Arthroosteitis, pustulotic, 784
- Arthropathy. *See also* Spondylarthropathy
 - familial, congenital camptodactyly and, 896
 - HLA-B27, IgA and IgM deficiency in, 1175
 - lead, 1048
 - post-bypass, 328
 - subcutaneous fat necrosis and, in pancreatitis, 121

Arthroplasty
 elbow, 364
 hip, 359
 total joint, 359
 total knee, 362
 Arthroscopy, 365
 Articular cartilage. *See* Cartilage
 Aseptic necrosis of bone, 283
 Aspirin. *See also* Acetylsalicylic acid; Salicylates
 effect on canine OA cartilage, 528, 994, 1231
 esterase of human erythrocyte, 541
 hydrolyzing enzyme, in human blood, 541
 hypothetical action of, 1300
 in RA, 937
 in SLE vascular disease, 1340
 Aspirin-induced type I collagen synthesis, 1231
 Assessment in gold therapy, 1308
 Asymptomatic hyperuricemia, 272
 Atrophy, glandular, of gastric mucosa in Sjögren's syndrome, 1196
 Auranofin, comparison with gold sodium thiomalate, 1303
 Autoantibodies
 anti-beta-2-microglobulin, 721
 to Jo-1 in polymyositis, 604
 liver disease and, 914
 in SLE, 306
 to type II collagen in rats, 1237
 Autoantibody specificity in CREST syndrome, 1
 Autoimmune abnormalities, anticentromere abnormalities and, 914
 Autoimmune disease
 diet and, 458
 familial SLE in males and, 39
 ocular abnormalities in mice with, 645
 therapy of, 258
 Autoimmune features of eosinophilic fasciitis, 688
 Autoimmune nephritis, dietary eicosapentaenoic acid and, 133
 Autoimmunity to proteins in RA, 494
 Avascular necrosis of bone, 283
 Azathioprine for RA, 937

B

B cells, Ia antigens, articular cartilage and, 1187
 B35M Ia positive human cell line, in RA, 486
 B7-CREG antigen in seronegative RA, 1412
 Backache, 240, 339. *See also* Low back pain
 Bacterial arthritis. *See* Infectious arthritis; Septic arthritis
 Bacterial cell wall peptidoglycans, polyarthritis induced by, 1442
 Band keratopathy in mice, 645
 Barbary ape, CPPD disease with concurrent vertebral hyperostosis in, 682
 Basement membrane-like material around small vessels in Lowe's (oculocerebrorenal) syndrome, 728
 Beclomethasone dipropionate for hoarseness, 1412

Bee venom, 1023
 Beef tallow diet, autoimmune nephritis in mice and, 133
 Behçet's syndrome, 340
 Benoxaprofen, proteoglycan synthesis in canine cartilage and, 771
 Benzathine penicillin G for secondary syphilis, 1530
 Beta-2-microglobulin in Felty's syndrome, 721
 Beta-thalassemia minor, arthritis in, 1292
 β -xyloside, in glycosaminoglycan synthesis, 522
 Biliary cirrhosis, primary, anticentromere antibodies in, 914
 Bioresearch Monitoring Program, 1360
 Bladder malignancy, cyclophosphamide in RA and, 804
 Blind loop revision, post intestinal bypass arthritis and, 678
 Bone
 aseptic necrosis of, 283
 CPPD disease and vertebral hyperostosis in Barbary ape, 682
 disorders of, 283
 formation in pancreatic arthritis, 129
 osteitis condensans ilii in apatite crystal deposition disease, 567
 tumors of, 286
 Bone marrow
 granulocyte/monocyte progenitor cells in SLE, 516
 Bone marrow-directed immune mechanisms in neutropenia of Felty's syndrome, 947
 Bone scans
 in aseptic necrosis of bone, 283
 of midcervical fracture, 756
 tuberculosis of greater trochanteric bursa and, 78
 Book Reviews
Amyloid and Amyloidosis: Proceedings of the Third International Symposium on Amyloidosis, 575
Pediatric Rheumatology for the Practitioner, 1536
Principles of Rheumatic Diseases, 240
Rheumatic Fever: A Guide to its Recognition, Prevention and Cure with Special Reference to Developing Countries, 1536
Rheumatology: A Primary Care Approach, 1296
Symposium on Idiopathic Low Back Pain, 240
 Brachial paralysis in giant cell arteritis, 207
 Bretium in SLE vascular disease, 1340
 Bursa, greater trochanteric, tuberculosis of, 77
 Bursitis, 335
 olecranon, CPPD deposition disease and, 695
 septic, 263
 tuberculous trochanteric, 77
 Butazolidin in rabbit model OA, 1382
 BXSB mice, 39, 257
 Bypass arthritis, post intestinal, effect of intestinal bypass revision on, 678

C

C57BL/6J-1pr/1pr mice, 745
 14 C-acetylsalicylic acid uptake in metatarsal cartilage in canine OA, 998

- ¹⁴C-acetylsalicylic acid (*cont'd*)
- ¹⁴C-amino acid, synovial proteoglycan and, 527
- ¹⁴C-dimethyl sulfoxide in adjuvant arthritis, 861
- Calcifications
- corneal, in mice with autoimmune disease, 648
 - costal, in osteitis condensans ilii, 568
 - nonosseous, 283
 - of quadriceps tendon in CPPD disease and vertebral hyperostosis, 684
- Calcinosis/dermatomyositis, 1220
- Calciphylaxis of rabbit synovial membrane, 1220
- Calcitonin
- in Paget's disease, 282
 - in rabbit OA, 1132
- Calcium
- in mice with autoimmune disease, 650
 - in synovial fluid, detection of, 191
- Calcium pyrophosphate dihydrate (CPPD) crystal deposition disease, 277. *See also* Chondrocalcinosis; Pseudogout
- concurrent vertebral hyperostosis in Barbary ape and, 682
 - inorganic pyrophosphate in blood platelets in, 564
 - olecranon bursitis and, 695
- Calcium pyrophosphate dihydrate (CPPD) crystals
- alizarin red S staining of, 191
 - in asymptomatic joints, 1522
- cAMP. *See* Cyclic adenosine phosphate
- Camptodactyly, congenital, familial arthropathy and, 896
- Cancer
- bladder, cyclophosphamide and, in RA, 804
 - systemic sclerosis and, 315
- Canine studies
- benoxaprofen stimulation of proteoglycan synthesis, 771
 - cartilage, 528, 994
 - collagen in articular cartilage of dog OA, 866
 - hyaluronate synthesis by synovial villi, 764
- Capillary microscopy in eosinophilic fasciitis, 617
- Captopril, in scleroderma renal crisis, 797
- Carbenoxolone sodium in rabbit model OA, 1382
- Carbonate in human synovial fluid, 1220
- Carbohydrate, glycosaminoglycan synthesis and, 522
- Cardiac involvement
- in hereditary amyloidosis, 1494
 - in RA, 293
 - in SLE with Reiter's syndrome, 1405
 - in systemic sclerosis, 313
- Cardiopulmonary involvement in systemic sclerosis, 795
- Cardiopulmonary resuscitation, spinal fractures in ankylosing spondylitis and, 751
- Carpal tunnel syndrome, 337
- in hereditary amyloidosis, 1494
 - in polymyalgia rheumatica, 1417
- Cartilage, 243
- aspirin and, in canine OA, 994
 - aspirin-induced type I collagen synthesis and, 1231
 - biochemical and morphologic studies of, 887
 - collagen
- Cartilage (*cont'd*)
- collagenase and, in human OA, 63
 - in dog model of OA, 866
 - proteoglycans and, 1111
- CPPD and vertebral hyperostosis in Barbary ape, 682
- cyanogen bromide peptides in, 892
 - degenerative changes in CPPD and vertebral hyperostosis, 682
 - disorders of, 285
 - effect of drugs on, 244, 528, 771, 994
 - femoral, 875, 887, 994
 - glycosaminoglycan in menisci in OA, 69
 - glycosaminoglycan metabolism, NSAID and, 528
 - glycosaminoglycan synthesis, nordihydroguaiaretic acid and, 771
 - in hereditary chondrocalcinosis, 1389
 - ilial, 887
 - immune complex and PMN interaction in, 1434
 - knee, 771, 1132
 - metatarsal, 994
 - nordihydroguaiaretic acid and, 771
 - in OA, 279, 1225
 - of rabbits, 875, 1132
 - pannus and, 472
 - peripheral joint, 887
 - proteinase in rabbit, 984
 - proteoglycan synthesis, 1111, 1225
 - drugs and, 528, 771
 - sacral, proteoglycans and link proteins in, 887
 - tumors of, 286
 - in type II collagen-induced arthritis, 1120, 1245
- Cartilage cells, Ia antigens and, 1187
- Cartilage degeneration
- articular, in rheumatic diseases, 191
 - glucocorticoids and, 1132
- Cartilage destruction, active cellular pannus and, in rheumatoid joints, 472
- Cartilage inhibitors, cartilage proteinases and, 990
- Cartilage-pannus junction, morphologic study of, 472
- Cartilage proteinase in immature rabbit articular cartilage, 984
- Catalase, natural killing activity and, in Sjögren's syndrome, 954
- Cathepsin D, metalloproteinases in rabbit articular cartilage and, 984
- Cationic polypeptides, plasma protein binding by MSU crystals and, 775
- CBA/H mice, 113
- Cefamandole for septic arthritis, 1410
- Cell-mediated immunity
- fibroblasts, leukocytes and, 22
 - in RA, 296
 - in temporal arteritis, 1201
- Cell morphology, cytotoxicity in rheumatic diseases and, 170
- Cell surface molecule, 1187

- Cellular immune system, 247
- Cellulitis, "cocktail sausage" digit in, 664
- Central nervous system
after pulse therapy in SLE, 809
in SLE, 303
- Central nervous system lupus, neutrophil aggregation in SLE and, 630
- Cervical radiculopathy in giant cell arteritis, 207
- Cervical spine, 367
in ankylosing spondylitis, 226, 751
lateral subluxation of, in psoriatic arthritis, 109
posterior longitudinal ligament ossification in, 226
in seronegative spondylarthropathy, 223
sternocostoclavicular hyperostosis, 784
- Cervicospinal circulation, 208
- CFU-C. *See* Granulocyte/monocyte progenitor cells
- CGS 5391B (experimental drug) in rabbit model OA, 1132, 1380
- CH50. *See* Serum hemolytic complement
- Charcot-Leyden crystals
in synovial fluid, 1416
versus corticosteroid crystals, 1533
- Chemotactic defects, joint pneumococcal pyarthrosis and, 1160
- Chemotaxis, inflammation and, 252
- Childhood dermatomyositis, nailfold capillary morphology in, 1169
- Children
osteomyelitis in, 262
septic arthritis in, 262
- Chloroquine, rabbit OA and, 1132
- Cholesterol "tophus," 1525
- Chondrocalcinosis
familial idiopathic, osteitis condensans ilii, apatite crystal deposition disease and, 567
hereditary, vertebral ankylosis in (correction), 112
HLA antigens in, 1392
inorganic pyrophosphate levels in, 564
in a Mexican-American family, 1387
- Chondrocytes, 243
aspirin-induced type I collagen synthesis and, 1231
benoxaprofen, protein and glycosaminoglycan synthesis and, 771
Ia antigens in cartilage and, 1187
loss in rabbit OA, 875
in Pond-Nuki dog OA, 872
proteoglycan synthesis of, in OA, 1225
type II collagen-induced arthritis and, 1245
- Chondroitin 4/6 sulfate, in proteoglycan, 522
- Chondroitin sulfate, in beagle OA, 69
type II collagen-induced arthritis and, 1245
- Chondrolysis, 286
- Chondromatosis, synovial, tricalcium phosphate in, 1220
- Chondrosarcoma
Ia antigens in cartilage and, 1187
protrusio acetabuli in, 1516
- Chronic obstructive pulmonary disease (COPD), musculo-skeletal and joint symptoms in, 1283
- Chrysotherapy. *See* Auranofin; Gold sodium thiomalate
- Circulating immune complexes (CIC)
corticosteroids and, in SLE, 637
in Felty's syndrome, 721
neutrophil aggregation in SLE and, 630
in polymyalgia rheumatica, 1472
serotonin content of platelets and, 532
in SLE relatives, 921
- Circulating macromolecular complexes in Felty's syndrome and RA, 721
- Cirrhosis, primary biliary, anticentromere antibodies in, 914
- Clinical medicine versus experimental medicine, 1297
- Clinical rheumatology, 550
- "Clone" formation in rabbit OA, 875
- Clostridial collagenase, proteoglycan synthesis in chondrocytes and, 1225
- Coagulation, NSAID and, 348
- Coagulation system activation, plasma protein binding and, 775
- Cobra venom factor in type II collagen-induced arthritis, 1120
- "Cocktail sausage" digit, 664
- Cohn Fraction II, 1490
- Colchicine, 352
for gout, 276
for hereditary chondrocalcinosis, 1391
rheumatoid synovial cells and, 8
- Cold stimuli, vasodilators and, in systemic sclerosis, 1037
- Collagen, 245
antibodies to in RA, 832
in articular cartilage in dog OA, 866
articular cartilage, proteoglycans and, 1111
autoimmunity and, in RA, 494
crosslinks, 246
digestion in human OA cartilage, 63
fibers, 1117
fibrils, 887
in human synovial fluid, 1220
interactions of, 246
in Lowe's (oculocerebrorenal) syndrome, 728
matrix breakdown, 866
metalloproteinases in rabbit articular cartilage and, 984
network, 1111
polyarthritis and, 694
reactivity of, 832
synthesis of, 246, 1231
type I
antibodies to, in rheumatic diseases, 832
aspirin-induced synthesis of, 1231
human, antikeratin antibodies and, 494
in dog OA, 866
in human OA cartilage, 63
type II, in adult sacroiliac cartilage, 887
antibodies to, in rheumatic diseases, 832

- Collagen (*cont'd*)
 types, III, IV, and V, antibodies to, in rheumatic diseases, 832
- Collagen-induced arthritis
 serum transfer of, 1237
 type II, 259, 1120, 1245
- Collagenase, 246
 in articular cartilage in dog OA, 866
 clostridial, proteoglycan synthesis in chondrocytes and, 1225
 in human OA cartilage, 63
 indomethacin and, 8
 mononuclear cell-stimulated synovial cells and, 15
 rabbit articular proteinases and, 989
 rheumatoid synovial cells and, 8
 synthesis
 phenytoin and, in RA, 118
 transforming growth factors and, 1374
- Collagenolytic activity
 in articular cartilage in dog OA, 866
 in human OA cartilage, 63
- Collagenous extracellular matrix, type II collagen-induced arthritis and, 1245
- Community hospital, rheumatologist in, 1033
- Complement, 250. *See also* Anti-complement
 antikeratin antibodies and, 494
 enzyme immunoassay in SLE and, 52
 immune complex solubilization capacity and, 156
 neutrophil aggregation in SLE and, 630
 in RA, 736
 in SLE, 45, 52, 302, 309, 736
 in type II collagen-induced arthritis, 1128
 C1, plasma protein binding and, 775
 C1q
 in Felty's syndrome, 721
 MSU crystals and, 775
 in SLE relatives, 921
 steroids and immune complexes in SLE, 637
 C1q solid phase assay, 169
 C1f, MSU crystals and, 775
 C1s, MSU crystals and, 775
 C2
 in ankylosing spondylitis, 1011
 deficiency, systemic lupus-like disease and, 1279
 C3
 in SLE, 45, 630
 in type II collagen-induced arthritis, 1120
 C4
 in ankylosing spondylitis, 1011
 in SLE, 45, 630
- Complement activation, plasma protein binding and, 775
- Complement receptors in rheumatic disease, 736
- Computed tomography in diagnosis of sacroiliitis, 760
- Congenital camptodactyly, familial arthropathy and, 896
- Congenital heart block in neonatal SLE, 210
- Connective tissue, 243
 argyrophilic fiber-rich, fibronectin in, 479
- Connective tissue activating peptide (CTAP)
 proteoglycans and, 522
 in scleroderma, 1362
- Connective tissue activation, 522
 in scleroderma, 1362
- Connective tissue disease. *See also* Mixed connective tissue disease; Overlap syndrome; Undifferentiated connective tissue disease
 anti-Jo-1 antibody in, 604
 cytotoxicity of sera in, 170
 Jo-1 antigen in, 604
 serum antibodies in, 506
 vasculitis and, 320
- Contraception in SLE, 304
- Cooperative Systematic Studies of Rheumatic Diseases, 1304
- Copper serum in RA, 933
- Copper bracelets, 1023
- Corneal calcifications in mice with autoimmune disease, 648
- Corticosteroid crystals versus Charcot-Leyden crystals, 1533
- Corticosteroid myopathy, 342
- Corticosteroids. *See also* Prednisone; Steroid drugs
 anti-proliferating cell nuclear antigen antibodies and, 140
 circulating immune complexes and, in SLE, 637
 creatine kinase levels and, in amyotrophic lateral sclerosis, 201
 in dermatomyositis, 961
 noninflammatory synovial effusions and, 1283
 in polymyositis, 961
 skin rash after methyl prednisolone in RA, 231
 in SLE, T cells and, 745
- CPPD. *See* Calcium pyrophosphate dihydrate
- Creatine kinase
 in amyotrophic lateral sclerosis, 201
 serum, in McLeod syndrome, 806
- Creatinine
 protein and in SLE, 919
 serum, in mice with autoimmune disease, 650
- Creatinine clearance and hyperuricemia in gout, 1057
- CREST syndrome
 anticentromere antibodies in, 1
 primary biliary cirrhosis and, 914
- Cryoglobulinemia, vasculitis and, 320
- Cryoglobulins, 250
 steroid drugs, immune complexes and, in SLE, 637
- Crystal-induced synovitis, cells in, 1321
- Crystal-plasma protein interactions, 775
- CTAP. *See* Connective tissue activating peptides
- Cubital tunnel syndrome, 337
- Cutaneous cholesterol granuloma, 1525
- Cutaneous lupus, anti-Sm and anti-RNP in, 848
- Cyanogen bromide peptides in cartilage, 892
- Cyclic adenosine phosphate, rheumatoid synovial cells and, 8
- Cycloheximide, metalloproteinases in rabbit articular cartilage and, 984

Cyclooxygenase inhibition, benoxaprofen, proteoglycan synthesis and, 771

Cyclophosphamide
 bladder malignancy and, in RA, 804
 in murine lupus, 1293
 in RA, 937

Cysts
 popliteal, 344
 rheumatoid synovial, 814

Cytochalasin B, morphologic changes in rheumatoid synovial cells and, 8

Cytochemical studies of temporal arteritis, 1201

Cytoplasmic granules in SLE, 623

Cytotoxin in murine lupus, 1341

Cytotoxic cells after total lymphoid irradiation in RA, 937

Cytotoxic drugs
 in psoriatic arthritis, 1052
 in RA, 937

Cytotoxicity
 of antilymphocyte antibodies to lymphoblasts in RA, 486
 natural. *See* Natural killer cell
 of sera in scleroderma, 170
 in Sjögren's syndrome, 954
 in SLE, T cells and, 745

D

Dairy products in RA, 462

Dapsone in giant cell arteritis and polymyalgia rheumatica, 689

Deformity, surgery and, in juvenile arthritis, 1140

Degenerative joint disease. *See also* Osteoarthritis
 antibodies to collagen in, 833
 effect of aspirin on canine OA cartilage, 994
 hereditary chondrocalcinosis and, 1389
 in rabbits, 875

Dental problems in SLE, 1506

Deoxycycline for septic arthritis, 1410

Dermatan sulfate
 in beagle OA, 69
 in proteoglycan, 522

Dermatomyositis, 316
 anti-Jo-1 antibody in, 604
 childhood, nailfold capillary morphology in, 1169
 dysgerminoma and, 572
 dysphagia in, 961
 esophageal abnormalities in, 961
 fibrosis in, 961
 juvenile, immunogenetic studies of, 214
 mortality in U.S., 1465

Dermatomyositis/calcinosis, crystals in, 1220

Dexamethasone, synovial fibroblast proliferation and, 1374

Diabetes mellitus, insulin-dependent, joint contractures and digital sclerosis in, 931

Diabetes mellitus, monosodium urate crystals and, 1523

Dialysis, alizarin red S staining in, 191

Dialysis-induced neutropenia in SLE, 630

Diet
 arthritis and, 1023
 autoimmune disease and, 1532
 autoimmune nephritis in mice and, 133
 in RA, 457, 1532

Diffuse erythematous rash, in childhood dermatomyositis, 1170

Diffuse idiopathic skeletal hyperostosis (DISH), 281
 with situs inversus, 811

Diffuse proliferative glomerulonephritis, idiopathic, anti-proliferating cell nuclear antigen in, 140

Diffuse scleroderma. *See also* Progressive systemic sclerosis; Scleroderma
 anticentromere antibodies in primary biliary cirrhosis and, 914
 anti-proliferating cell nuclear antigen and, 140

Digital sclerosis in adult insulin-dependent diabetes mellitus, 932

Digital ulcers
 nifedipine for, in scleroderma, 809
 in Raynaud's phenomenon, 1177

Digital vasospasm, in Raynaud's phenomenon, 1177

Dimethyl sulfoxide (DMSO), 693
 in adjuvant arthritis, 861
 public's perception of, arthritis and, 1023
 sulindac and, in peripheral neuropathy, 791

Diphosphonate in Paget's disease, 282

Disability assessment, 241

Disability score, in juvenile arthritis, 1140

Discs, intervertebral, CPPD and, in Barbary ape, 682

Discoid lupus. *See also* Cutaneous lupus
 C2 deficiency in, 1279

Disease-modifying antirheumatic drugs, 352

Diseases of connective tissue, 247

DISH. *See* Diffuse idiopathic skeletal hyperostosis

DMSO. *See* Dimethyl sulfoxide

DNA
 antibody to, in SLE, 45
 cytotoxicity in scleroderma and, 170
 double-stranded, antibodies to, 848
 native, enzyme immunoassay for antibodies to, 52
 single-stranded
 antibodies to, 848
 platelet release reaction and, 179

DNA complexes, in SLE, RA, and hematologic malignancies, 736

Double-stranded DNA (dsDNA). *See* DNA

Drug trials, Phase III design, 1354

Drug-induced lupus, 305
 antibodies to Sm and RNP in, 848

Drugs, 345
 algestone acetate, 1380
 allopurinol, 277
 Amstat, 1380
 antacids, 961
 antibiotic, 557
 anti-estrogens, 1132

Drugs (*cont'd*)

antihypertensive, 1340
antiinflammatory, 296
antimalarial, 356
antirheumatic, 1132
antithrombotic, 1340
Anturan, 1340
aprotinin, 1380
Aristospan, 1380
aspirin, 994, 1340
auranofin, 1303
azathioprine, 937
beclomethasone dipropionate, 1412
benoxaprofen, 771
benzathine penicillin G, 1530
bretylum, 1340
Butazolidin, 1380
calcitonin, 282
captopril, 797
carbenoxolone sodium, 1380
cefamandole, 1410
CGS 5391B, 1132, 1380
chloroquine, 1132
colchicine, 8, 276, 352, 1391
corticosteroid, 140, 201, 231, 342, 637, 745, 961, 1283
cyclophosphamide, 804, 937, 1293
cytochalasin B, 8
cytotoxic, 937, 1052
cytoxan, 1340
dapsone, 689
deoxycycline, 1410
dexamethasone, 1374
dimethyl sulfoxide (DMSO), 693, 791, 861
diphosphonate, 282
disease-modifying antirheumatic, 352
effects of on cartilage, 244
fenoprofen, 234
glucocorticoids, 1132, 1380
glucocorticosteroids, 357
glucofuranoside derivatives, 1132
gold sodium thiomalate, 1132, 1303
GPA 2163, 1380
haloperidol, 357
heparin, 1340
hypouricemic, 352
ibuprofen, 350
imipramine, 182
immunosuppressive, 356, 961, 1340
indomethacin, 8, 350, 528, 861, 954, 1374, 1390, 1410
Ismelin, 1341
isoxicam, 1288
levamisole, 356
methotrexate, 691, 1269, 1275, 1291
methyl prednisolone, 117, 231
mithramycin, 282
naproxen, 350, 1054
in neutropenia of Felty's syndrome, 951

Drugs (*cont'd*)

nifedipine, 794, 809, 1177
nomifensine, 936
nonsteroidal antiinflammatory, 345, 1380, 1415
in OA rabbit model, 1380
orgotein, 1132, 1382
orphan, 206
Palosein, 1380
paramethasone acetate, 1132, 1380
penicillamine, 355, 581, 593, 801, 937, 1132
pentosan polysulfate, 1380
phenacetin, 352
phenylbutazone, 1380
phenytoin, 118
pirprofen, 1132, 1380
prednisone, 745, 806, 1519
propranolol, 1340
proquazone, 1288
in RA, 1303
Rengasil, 1380
salicylates, 348, 528
sodium salicylate, 528
SP 54, 1382
steroids, 117, 623, 637, 689, 1132, 1173, 1380
sulindac, 351, 791, 1413
superoxide dismutase, 1132, 1382, 1385
tamoxifen, 1132, 1380
Ticlopidine, 1341
tolmetin, 350
tranexamic acid, 1380
Trasylol, 1382
triamcinolone, 1132, 1380
tribenoside, 1132, 1380
uricosuric, 277
zomepirac, 1288
Dry eyes in Sjögren's syndrome in scleroderma, 500
Dysfunctional uterine bleeding, in RA with amyloidosis, 1295
Dysgerminoma, dermatomyositis and, 572
Dysphagia in polymyositis and dermatomyositis, 961

E

Ear, in RA, 292
EBV. *See* Epstein-Barr virus
Ecto 5'-nucleotidase, 270
Effector cells in Sjögren's syndrome, 954
Eicosapentaenoic acid, autoimmune nephritis in mice and, 133
Elbow, psoriatic lesion of, 785
Elbow arthroplasty, 364
Elderly, gold therapy in, 705
Electron microscopy
 of active cellular pannus, 472
 in articular cartilage study, 1115
 in dog OA, 866
 in Lowe's (oculocerebrorenal) syndrome, 728

- ELISA. *See* Enzyme-linked immunosorbent assay
- Empire Rheumatism Council gold therapy trial, 1311
- Encephalopathy in lead arthropathy, 1048
- Enchondroma, Ia antigens in cartilage and, 1187
- Endocrine disorders in rheumatic diseases, 344
- Endocrine glands, Sjögren's syndrome and, 1196
- Endometrial biopsy, in diagnosis of secondary amyloidosis, 1295
- Endothelial cells
in diseased synovia, 1427
in inflammation, 1002
in RA, 479
in sclerodema, 170
- Enteric arthritis, 328, 1163
- Environmental factors in SLE, 309
- Enzymatic digestion, articular cartilage collagen, proteoglycan and, 1111
- Enzyme activity in collagen of dog OA cartilage, 866
- Enzyme hydrolysis studies of proteoglycans, 522
- Enzyme immunoassay for antibodies to native DNA, 52
- Enzyme-linked immunosorbent assay (ELISA)
in detection of anti-SS-B antibodies, 146
type II collagen-induced arthritis and, 1120, 1242
- Enzymes
aspirin hydrolysis and, 541
inflammation and, 252
mononuclear cell-stimulated synovial cells and, 15
plasminogen, collagenase and, in synovial cells, 15
- Eosinophilic fasciitis, 343
autoimmune features of, 688
capillary microscopy in, 617
- Epidemiology
of RA, 290
of Reiter's syndrome, 325
- Epidemiology studies
dermatomyositis, 316
giant cell arteritis, 1214
gout, 273
juvenile arthritis, 1208
polymyositis, 316
rheumatic fever, 333
serum uric acid levels, 87
SLE, 301
- Epidermal growth factor, effect on synovial fibroblasts, 1370
- Epinephrine-induced ³H-serotonin release, 179
- Epiphyseolysis, secondary OA and, 910
- Epstein-Barr virus
in infectious mononucleosis, 554
in RA, 712, 1091
- Erosions
in dog OA, 866
in hereditary amyloidosis, 1145
HLA antigens and, in RA, 1053
in rabbit OA, 875
in type II collagen-induced arthritis, 1120
- Erosive osteoarthritis
gout in Heberden's nodes and, 94
in hereditary amyloidosis, 1145
in PSS, 1041
- Erosive polyarthritis, seronegative, pyoderma gangrenosum and, 813
- Erosive synovitis in hereditary amyloidosis, 1145
- Erythema in childhood dermatomyositis, 1170
- Erythema nodosum in histoplasmosis, 1065
- Erythropoiesis, anemia in RA and, 28
- Esophageal involvement
in Behçet's syndrome, 690
in polymyositis and dermatomyositis, 961
- Esterase hydrolysis, aspirin and, 541
- Estradiol, in testosterone metabolism, 1518
- Estrone, in testosterone metabolism, 1518
- Ethanol consumption, urate clearance and, in gout, 1057
- Ethnic groups, antibodies in, 509
- Exercise, hereditary chondrocalcinosis and, 1389
- Experimental amyloidosis, 332
- Experimental medicine versus clinical medicine, 1297
- Experimental models. *See* Animal models
- Extracellular matrix, proteoglycan content of, 528
- Extrapneumatic inflammation in pancreatic arthritis, 127
- Eye
in mice with autoimmune disease, 645
in RA, 292
in Sjögren's syndrome in scleroderma, 500
in systemic sclerosis, 313

F

- F344 rats, 815
- Fab fragments, anti-Ia heteroantiserum and, 486
- Factor B in ankylosing spondylitis, 1011
- Familial arthropathy, congenital camptodactyly and, 896
- Familial chondrocalcinosis
inorganic pyrophosphates in, 564
osteitis condensans ilii, apatite crystal deposition and, 567
- Familial mediastinal fibrosis, seronegative spondylarthropathy and, 221
- Familial Mediterranean fever, 340
- Schönlein-Henoch syndrome and, 1536
- Familial rheumatic disorders, 344
- Familial SLE in males, 39. *See also* Genetics
- Fasciitis, eosinophilic. *See* Eosinophilic fasciitis
- Fat, dietary, and autoimmune disease, 1532
- Fat necrosis, pancreatitis and, 121
- Fatigue, total lymphoid irradiation in RA and, 937
- Fatty acids in pancreatic arthritis, 121, 127
- Fc binding, Ia specific antilymphocyte antibodies in RA and, 486
- Fc receptor-bearing lymphoid cells, IgM rheumatoid factor, rosette formation and, 1098
- FDA Arthritis Advisory Committee Meeting, 206, 1288, 1397

Felty's syndrome. *See also* Rheumatoid arthritis.
 beta-2-microglobulin in, 721
 circulating immune complexes in, 721
 neutropenia of, immune mechanisms in, 947
 total lymphoid irradiation and, in RA, 937

Femoral condyle
 aspirin, glycosaminoglycan metabolism and, in cartilage, 994
 collagenase in cartilage of dog OA, 866
 CPPD, vertebral hyperostosis and, in Barbary ape, 684
 in pancreatic arthritis, 129

Femoral head
 monoclonal antibodies and, 1187
 osteonecrosis of, 913
 osteophytosis of, 908

Fenoprofen, acute renal failure after, 234

Fibrillation
 in dog OA, 866
 in rabbit OA, 875

Fibrils
 collagen, in ilial cartilage, 887
 in Lowe's (oculocerebrorenal) syndrome, 728

Fibrin in rheumatoid synovial membrane and synovial fluid, 479

Fibrinogen, MSU crystals and, 775

Fibroblast activating factor production, 1449

Fibroblast proliferation, induction by human mononuclear leukocyte-derived proteins, 22

Fibroblast-like cells in cartilage destruction at pannus junction, 472

Fibroblastoid cells, Ia antigens, articular cartilage and, 1187

Fibroblasts
 cytotoxicity of sera in scleroderma and, 170
 foreskin, 170
 leukocytes, cell-mediated immune reactions and, 22
 skin, in scleroderma, 1362
 synovial, transforming growth factors and, 1370

Fibronectin
 MSU crystals and, 775
 in rheumatoid synovial membrane and synovial fluid, 479

Fibrosis
 in dermatomyositis, 961
 mediastinal, 1292
 in polymyositis, 604, 961
 in seronegative spondylarthropathy, 221
 in Sjögren's syndrome and scleroderma, 500

Fibrositis, clinical characteristics of, 817

Fibrous tissue
 in Lowe's (oculocerebrorenal) syndrome, 728
 tendons and, in congenital camptodactyly, 896

Fibular collateral ligaments, in rabbit OA, 875

Finger plethysmography, nifedipine and, in Raynaud's phenomenon, 1177

Fisher 344 rats, 815

Flexor tendons in camptodactyly, 899

Folic acid deficiency in RA, 1532

Food additives and RA, 462

Food and Drug Administration, Phase III drug trials, 1354

Foot surgery, 364

Fractures
 femoral neck, Ia antigens in cartilage and, 1187
 spinal, in ankylosing spondylitis, 751

Free fatty acids in pancreatic arthritis, 127

Functional ability in RA, 937

Fungal arthritis, 265

G

Galactosamine in beagle OA, 73

⁶⁷Gallium lung scans in PSS, 969

Gangrenosum, pyoderma, seronegative erosive polyarthritis and, 811

Gastric mucosa in Sjögren's syndrome, 1196

Gastrointestinal involvement
 in bacterial arthritis, 1259
 in RA, 294
 in rheumatic disease, 344
 in systemic sclerosis, 312

Gastrointestinal side effects of NSAID, 347

Gelatin, metalloproteinases in rabbit articular cartilage and, 984

Genetics
 cyclophosphamide in murine lupus, 1293
 HLA antigens in juvenile arthritis, 35
 HLA-B27 positive ankylosing spondylitis, 1460
 psoriatic arthritis and, 328
 rheumatoid factor in mice, 1084
 SLE and, 309
 twins discordant for, 1399

Giant cell (temporal) arteritis, 322, 1201

brachial paralysis in, 207

cervical radiculopathy in, 207

dapsone in, 689

epidemiology studies of, 1214

HLA-DR3 and HLA-DR4 in, 925

polymyalgia rheumatica and, 1472

resistance to treatment, 930

Glandular atrophy, in gastric mucosa in Sjögren's syndrome, 1196

Glandular fibrosis in Sjögren's syndrome in scleroderma, 500

Glomerular index, dietary eicosapentaenoic acid in autoimmune disease in mice, 135

Glomerulonephritis. *See also* Kidney; Nephritis; Renal antihypertensive agents and, 1340
 idiopathic diffuse proliferative, 140

Glucocorticoids in rabbit OA, 1132, 1382, 1385

Glucocorticosteroids, 357

Glucofuranoside derivatives in rabbit OA, 1132

Glucosamine in beagle OA, 73

- Glycosaminoglycan metabolism
in articular cartilage, NSAID and, 528
aspirin and, in canine OA cartilage, 994
- Glycosaminoglycan synthesis, 244
aspirin and, 994
nordihydroguaiaretic acid and, 771
by PSS fibroblasts, 1362
sodium salicylate and, 528
- Glycosaminoglycans
in adult sacroiliac cartilage, 887
hyaluronate synthesis by synovial villi and, 764
in menisci in OA, 69
in mouse skin, 653
sulfated, proteoglycan synthesis and, 522
- Glycosylation, of hydroxylysine, in type II collagen-induced arthritis, 1245
- Glyoxalase-I in ankylosing spondylitis, 1011
- Gold, 352. *See also* Auranofin; Gold sodium thiomalate; Sodium aurothiomalate; Triethylphosphine gold
phagocytosis and, 82
- Gold pneumonia, 1310
- Gold sodium thiomalate
comparison with auranofin, 1303
in rabbit OA, 1132
- Gold therapy
in elderly patients, 705
neurologic complications of, 825
in RA, 937
repeat, 1071
- Gold toxicity, 705, 825, 1074, 1309
- Gonococcal arthritis, 263
diagnosis of, 1499
- Gout, 272
alcohol ingestion and hyperuricemia in, 1057
alizarin red S staining in, 191
allopurinol in, 277
anemia in, 1057
anticollagen antibodies in, 832
clinical aspects of, 273, 1059
"cocktail sausage" digit in, 664
colchicine in, 276
CPPD deposition and, 1387
earliest description of, 236
epidemiology of, 273
ethanol clearance and, 1057
in Heberden's nodes, 94, 1413
hypertension in, 1057
hyperuricemia in, 1057
interleukin-1-like factor in, 975
kidney and, 274
laboratory findings in, 1059
lead, hyperuricemia and, 1057
nonarticular, in RA, 98
obesity and, 1057
Paget's disease of bone and, in SLE, 238
- Gout (*cont'd*)
peripheral neuropathy in, 1057
and RA, 98, 275
renal function and lead excretion in, 1061
renal stones in, 274
in SLE, 238
synovial fluid lactic acid in, 1500
tophaceous, in sickle cell-thalassemia, 928
urate crystals and, 272
- Gouty arthritis, 1057
hyperuricemia, tophus and, in nonarticular gout, 98
in OA, 94
- GPA 2163, in rabbit model OA, 1380
- Gram-negative arthritis, 264
- Granulocyte chemotaxis, medullasin and, 1002
- Granulocyte/monocyte progenitor cells (CFU-C) in bone marrow in SLE, 516
- Granulomatosis. *See also* Vasculitis
Wegener's, HLA-DR2 antigen in, 102
- Granulomatous vasculitides, 321
- Granulopoietic failure in SLE, 516
- Grip strength, penicillamine in RA and, 581
- Group A streptococcal cell wall-induced polyarthritis, 1442
- Growth factor, T cell and joint fluid, 977
- Guidelines for the Clinical Evaluation of Anti-inflammatory and Anti-rheumatic Drugs (Adults and Children), 206
- Guillain-Barré-like syndrome, complication of gold therapy, 825
- Gunshot wounds, lead arthropathy and, 1048
- Gynecomastia, methotrexate and, 691

H

- H-2 genotype, rheumatoid factor and, in mice, 1085
- Haloperidol, 357
- Hand
in congenital camptodactyly, 898
erosive OA in PSS, 1042
joint involvement of, in diabetes, 931
in Lowe's (oculocerebrorenal) syndrome, 728
soft tissue disorders of palm, 336
- Headache in fibrositis, 817
- Health Assessment Questionnaire, modification of, 1346
- Health planning, musculoskeletal diseases and, 901
- Health status, pain and, 1017
- Heart. *See* Cardiac; Cardiopulmonary; Pleuropericarditis
- Heat stability studies, fibroblast proliferation and, 26
- Heberden's nodes, gout and, 94, 1413
- Helper cells, 248. *See also* T cells
in RA, after total lymphoid irradiation, 937
in SLE, 745
- Hematologic malignancies, antibody/DNA complexes and erythrocytes in, 736

- Hematologic studies
 - in RA, 294
 - in SLE, 303
 - in systemic sclerosis, 313
- Hematology toxicity from gold in the elderly, 705
- Hemochromatosis, CPPD deposition and, 1387
- Hemodynamic findings, vascular reactivity, and pulmonary hypertension in systemic sclerosis, 1037
- Hemoglobinopathies, gout and, 929
- Hemolysis in McLeod syndrome, 806
- Hemolytic activity of complement, immune complexes in RA and, 156
- Hemolytic anemia
 - anti-proliferating cell nuclear antigen and, 140
 - naproxen and, 1054
- Henophilus parainfluenzae* in septic arthritis, 1502
- Henoch-Schönlein purpura, IgA production in, 854
- Heparin in murine lupus, 1341
- Hepatitis, total lymphoid irradiation in psoriatic arthritis and, 1052
- Hepatosplenomegaly, neonatal, inflammation and, 668
- Hepatotoxicity, proquazone and, 1288
- Herbs in RA, 462
- Hereditary chondrocalcinosis. *See* Chondrocalcinosis
- Heredity and urate clearance in gout, 1057
- Heredofamilial amyloid, 332, 1145
- Herpes zoster, acute monarticular arthritis and, 236
- Heterophil-negative infectious mononucleosis, symmetric polyarthritis and, 553
- HEV. *See* High endothelial venules
- Hexosamines
 - benoxaprofen, proteoglycan synthesis and, 771
 - hyaluronate synthesis and, 764
 - in skin of TSK mice, 653
- Hidden rheumatoid factor in juvenile arthritis, 165
- High endothelial venules (HEV) in diseased synovia, 1427
- Hill, Donald Frederick (In Memoriam), 1290
- Hip
 - in ankylosing spondylitis, 186, 755
 - arthroplasty of, 359
 - gunshot wounds to, lead arthropathy and, 1048
 - in juvenile arthritis, 814, 1140
 - monoclonal antibodies and, 1187
 - rheumatoid synovial cyst of, 814
 - septic arthritis in, 1044
 - tuberculosis of greater trochanteric bursa, 77
- Histoplasmosis, rheumatologic manifestations of, 1065
- HLA antigens
 - family pedigree, 211
 - in juvenile arthritis, 35
 - in RA, 1053
 - in SLE, 1104
 - with Reiter's syndrome, 1405
 - with thrombocytopenia, 1184
 - in twins discordant for, 1400
- HLA antigens (*cont'd*)
 - in systemic sclerosis, 313
 - in systemic vasculitis, 102
- HLA-A antigens in ankylosing spondylitis, 1011
- HLA-A3 in Wegener's granulomatosis, 103
- HLA-B antigens in ankylosing spondylitis, 1011
- HLA-B7 in Wegener's granulomatosis, 103
- HLA-B27
 - in ankylosing spondylitis, 1011, 1460
 - arthropathy, IgA and IgM deficiency in, 1175
 - chronic arthritis and, 1322, 1324
 - in juvenile arthritis, 35
 - mesangial IgM nephropathy and, 1056
 - Reiter's syndrome and, 1460, 1463
- HLA-C antigens in ankylosing spondylitis, 1011
- HLA-DR antigens
 - autoantibody expression and, 1533
 - in juvenile arthritis, 35
 - in juvenile dermatomyositis, 214
 - in polymyalgia rheumatica-giant cell arteritis, 925
 - in RA, 486, 1053
 - in SLE, 1533
- HLA-DR2 in Wegener's granulomatosis, 102
- HLA-DR3
 - neonatal lupus and, 210
 - in polymyalgia rheumatica-giant cell arteritis, 925
- HLA-DR4
 - antikeratin antibodies and, 494
 - in juvenile arthritis, 35
 - in polymyalgia rheumatica-giant cell arteritis, 925
 - in RA, 494, 1053
- HLA-linked genes in SLE, 1104
- HNK-1⁺ lymphocytes, in SLE, 623
- (HNK 1-Leu 7) monoclonal antibodies, 1173
- Hoarseness, treatment in rheumatic diseases, 1412
- Homozygous C2 deficiency, systemic lupus-like disease and, 1279
- Hormones in SLE
 - antidiuretic, 1055
 - in twins discordant for, 1399
- Hospitals, community, rheumatologist in, 1033
- Host defense mechanisms, in multi-joint pneumococcal pyarthrosis, 1160
- Humoral immune system, 249
- Hyaluronate, 245
 - in beagle OA, 74
 - synthesis, synovial villi in, 764
- Hyaluronic acid
 - in beagle OA, 69
 - benoxaprofen, proteoglycan synthesis and, 771
 - PSS fibroblast synthesis of, 1362
- Hyaluronidase
 - fibronectin and, in synovial membrane, 479
 - indomethacin, GAG synthesis and, 528
 - testicular, 1111

Hydrated proteoglycans, collagen network and, 111
 Hydrogen peroxide, natural killing activity and, in Sjögren's syndrome, 954
 Hydrolytic alteration, hydroxyapatite nucleation and, 1220
 Hydroxyapatite crystals, 278
 in apatite deposition disease, 195
 in synovial fluid, 1220
 Hydroxyl, in human synovial fluid, 1220
 Hydroxylysine, glucosylation of in type II collagen-induced arthritis, 1245
 Hypergammaglobulinemia in RA, possible pathogenesis, 1490
 Hypermobile joints in Lowe's (oculocerebrorenal) syndrome, 728
 Hyperostosis
 DISH, situs inversus in, 811
 skeletal, CPPD disease and, 682
 sternocostoclavicular, 784
 vertebral, CPPD disease and, 682
 Hyperparathyroidism, CPPD deposition and, 1387
 Hypersensitivity in RA
 delayed, to methyl prednisolone, 231
 after pulse therapy, 1269
 Hypertension
 in gout, 1057
 in murine lupus, 1340
 in PSS, 794, 1037
 Hyperthermia, malignant, 342
 Hyperuricemia
 asymptomatic, 272
 in gout, 1057
 monosodium urate crystals in, 1523
 in nonarticular gout, 98
 Hypocomplementemic vasculitis-urticaria syndrome, 321
 Hypomagnesemia, CPPD deposition and, 1387
 Hypophosphatasia, CPPD deposition and, 1387
 Hypouricemia, 271
 Hypouricemic agents, 352
 Hypoxanthine guanine phosphoribosyl transferase, 266

I

Ia positive (B35M) negative and (MOLT4) human cell line in RA, 486
 Ibuprofen, 350
 Idiopathic chondrocalcinosis, familial, osteitis condensans ilii, apatite crystal deposition disease and, 567
 Idiopathic diffuse proliferative glomerulonephritis, anti-proliferating cell nuclear antigen in, 140
 Idiopathic protrusio acetabuli, 1514, 1516
 Idiopathic thrombocytopenic purpura, familial SLE in males and, 39

IgA. *See also* Immunoglobulins
 in Henoch-Schönlein purpura, 854
 in HLA-B27 arthropathy, 1175
 IgA rheumatoid factor, 1086
 IgA vasculitis, 321
 IgG. *See also* Immunoglobulins
 alpha-interferon and, 1091
 ANA, RNP and, 509
 anticollagen, 1120
 antikeratin antibodies and, 494
 in collagen-induced arthritis, 1120, 1237
 heat aggregated, ³H-serotonin release and, 179
 in Henoch-Schönlein purpura, 854
 Ia specific antilymphocyte antibodies and, 486
 in juvenile arthritis, 35, 165
 plasma protein binding and, 775
 in RA, 486, 836, 1091
 total lymphoid irradiation and, 943
 serotonin content of platelets and, 532
 IgG-containing immune complexes, binding of, 1098
 IgM rheumatoid factor and, 1098
 IgG rheumatoid factor
 in mice, 1085
 penicillamine and, in RA, 593
 Igh-1 genotype, rheumatoid factor and, in mice, 1085
 IgM. *See also* Immunoglobulins
 alpha-interferon and, in RA, 1091
 anemia and, 28
 in Henoch-Schönlein purpura, 854
 in HLA-B27 arthropathy, 1175
 HLA-DR4 and, 35
 Ia specific antilymphocyte antibodies and, 486
 in juvenile arthritis, 35, 165
 in RA, 28, 486, 1091
 penicillamine and, 593
 total lymphoid irradiation and, 943
 rosette formation and, 1098
 IgM nephropathy in HLA-B27 spondylarthropathy, 1056
 Iliac cartilage, 887
 Imipramine, ³H-serotonin release and, 182
 Immune complex disease, platelet release reaction and, 179
 Immune complexes, 249
 antibodies against RNP and, 509
 antibody/³H-dsDNA, 736
 anti-Fab' antibodies and, 1481
 containing 19S IgM rheumatoid factor-IgG, 165
 in Felty's syndrome, 721
 IgG-containing, binding of, rosette formation and, 1098
 natural killing activity and, 954
 neutrophil aggregation and, 630
 polymorphonuclear leukocytes and, 1434
 in RA, 156, 630, 721, 1481
 in Sjögren's syndrome, 954
 in SLE, 45, 306, 637
 in SLE relatives, 921

- Immune complexes (*cont'd*)
 in small vessel vasculitis, 320
 solubilization capacity, 156
 steroid drugs and, 637
- Immune function, leukapheresis in RA and, 1076
- Immune mechanisms, bone marrow-directed, in neutropenia of Felty's syndrome, 947
- Immune network, hypothesis of, 1301
- Immunogenetic studies
 of juvenile dermatomyositis, 214
 of RA, 297
- Immunoglobulin heavy chain locus in mice, 1085
- Immunoglobulin synthesis
 in RA, after total lymphoid irradiation, 937
 in twins discordant for SLE, 1401
- Immunoglobulins
 in collagen-induced arthritis, 1120, 1237
 in Henoch-Schönlein purpura, 854
 lymphoplasmaphoresis effect on, 1421
 in RA, 496, 1091
- Immunoperoxidase staining
 for fibronectin in RA, 479
 of gastric mucosa in Sjögren's syndrome, 1196
- Immunoprecipitates in rheumatoid synovial fluid, 483
- Immunoreactive polypeptides, anti-SS-B antibodies and, 146
- Immunoreactive trypsin in pancreatitis, 121
- Immunoregulation
 in PSS, 841
 in RA, 486
 in SLE, 745
- Immunosuppression, leukapheresis in RA and, 1076
- Immunosuppressive drugs, 356
 in polymyositis and dermatomyositis, 961
- IND. *See* Investigational Exemption for a New Drug
- Indiana type hereditary amyloidosis, 1493
- Indomethacin, 350
 in adjuvant arthritis, 861
 collagenase and, 8
 for hereditary chondrocalcinosis, 1390
- matrix proteoglycans, articular cartilage and, 528
 prostaglandin E2 and, 8
 for septic arthritis and pseudogout, 1410
 Sjögren's syndrome and, 954
 synovial fibroblast proliferation and, 1374
 topical application, 861
- Industrial soft tissue injuries, 336
- Infection
 in juvenile arthritis, 1140
 muscle, 341
 RA and, 295
 tuberculosis of greater trochanteric bursa, 77
- Infectious arthritis, 261. *See also* Septic arthritis
Kingella kingae, 557
Serratia liquefaciens, 1166
Yersinia enterocolitica, 1163
- Infectious mononucleosis, symmetric polyarthritis and, 553
- Infectious pneumarthrosis, 1166
- Inflammation, 251
 bacteria and, 1259
 chronic
 in gouty tophus in renal medulla, 99
 mononuclear cell-stimulated synovial cells and, 15
 in Sjögren's syndrome, 1196
 eicosapentaenoic acid and, 133
 fibronectin and, 479
 glycosaminoglycans in beagle OA and, 69
 gold compounds and, 82
 in hereditary amyloidosis, 1145
 joint fluids, lipids in, 121
 Lowe's (oculocerebrorenal) syndrome and, 728
 medullasin in granulocytes in, 1002
 muscle, anti-Jo-1 antibody in, 608
 neonatal onset multisystem, 668
 plasminogen activator, collagenase and, 15
 platelets, DNA at site of tissue injury and, 179
 pregnancy and, 1155
 serotonin content of platelets in, 532
 Sjögren's syndrome and, in scleroderma, 500
- Inflammatory bowel disease, arthritis and, 328
- Inflammatory cell infiltration
 Lowe's (oculocerebrorenal) syndrome and, 728
 in temporal arteritis, 1201
- Inflammatory reaction
 in pancreatic arthritis, 127
 to streptococcal cell walls, 1442
- Inpatient consultative rheumatology training, 658
- Insulin-dependent diabetes mellitus, joint contractures preceding, 931
- Interferon
 dietary fat and, 1532
 human alpha, IgM rheumatoid factor and in RA, 1091
 lymphopenia and, in SLE, 1415
 NK cell activity and, 1452
 peripheral blood lymphocytes and in SLE, 575
- Interleukin-1, hypothetical action of, 1299
- Interleukin-1-like factor in human joint effusions, 975
- Interleukin-2, NK cell function in SLE and, 1316
- Intersternocostoclavicular ossification, 784
- Interstitial pulmonary fibrosis with polymyositis, 604
- Intervertebral discs, CPPD and, in vertebral hyperostosis, 682
- Intestinal bypass, effect of revision on post intestinal bypass arthritis, 678
- Intestinal isoenzyme of alkaline phosphatase in RA, 574
- Intraarticular injection of drugs
 local skin rash after, 231
 in rabbit model OA, 1380
- Intrahepatic aneurysm, polyarteritis nodosa complicated by, 106
- Intrauterine tenosynovitis, congenital camptodactyly and, 896
- Intravascular leukoaggregates, morbidity in SLE and, 630

Investigational Exemption for a New Drug (IND), 1355
 Iridocyclitis in juvenile arthritis, 36
 Iritis in ankylosing spondylitis, 186
 Irradiation, total lymphoid
 in psoriatic arthritis, 1052
 in RA, 937
 Irritable bowel syndrome in fibrositis, 817
 Ismelin in murine lupus, 1341
 Isoenzymes
 intestinal, of alkaline phosphatase in RA, 574
 of lactate dehydrogenase in T cells in SLE, 932
 Isoxicam, 1288

J

Jejunioileal bypass, arthritis after, 678
 Jo-1 antigen in connective tissue diseases, 604
 Joint aspiration, rheumatology education and, 658
 Joint effusions
 congenital camptodactyly and, 896
 human, interleukin-1-like factor in, 975
 interleukin-1, 975
 in Lowe's (oculocerebrorenal) syndrome, 728
 Joint erosions, in hereditary amyloidosis, 1145
 Joint pathology
 drugs and, in rabbit OA, 1132
 knee in rabbit OA, 875
 Joint physiology in OA, 279
 Joint scans, in hereditary amyloidosis, 1145
 Joint scores, penicillamine and in RA, 593
 Joint structure and function, 242
 Joint swelling
 in Lowe's (oculocerebrorenal) syndrome, 728
 in RA, 937
 penicillamine and, 581
 Joint-restricted RA, beta-2-microglobulin in, 721
 Joints
 in chronic obstructive pulmonary disease, 1283
 glycosaminoglycan synthesis and, 69, 528
 in gouty arthritis, 94
 hand, in diabetes, 931
 in histoplasmosis, 1057
 hypermobile, 728
 in infectious arthritis, 262
 inflammation, pregnancy and, 1155
 interphalangeal, 94, 581, 1155
 knee, in congenital camptodactyly, 897
 in Lowe's (oculocerebrorenal) syndrome, 728
 metacarpophalangeal, 1147
 in OA, 94
 rheumatoid, cartilage destruction in, 472
 sacroiliac, 222, 760, 787, 887
 temporomandibular, 344
 Juvenile arthritis, 287. *See also* Juvenile dermatomyositis;
 Rheumatoid arthritis
 antibodies to Sm and RNP in, 848

Juvenile arthritis (*cont'd*)
 beclomethasone dipropionate for, 1412
 classification of, 287
 epidemiology of, 1208
 historical accounts of, 1266
 HLA antigens in, 28
 neonatal onset multisystem inflammatory disease and, 668
 prevalence of, 599
 protrusio acetabuli in, 1512
 rehabilitation of hip in, 814
 synovial fluid lactic acid in, 1502
 synovitis in, 1321
 total knee arthroplasty in, 1140
 Juvenile dermatomyositis, immunogenetic studies of, 214
 Juvenile rheumatoid arthritis. *See* Juvenile arthritis

K

K562 cells
 natural killing activity and, in Sjögren's syndrome, 954
 in SLE, 623
 Kawasaki's disease, 320
 Keratan sulfate
 in beagle OA, 69
 type II collagen-induced arthritis and, 1245
 Keratitis overlying band keratopathy in mice with autoimmune disease, 649
 Kidney. *See also* Renal
 in gout, 274
 in RA, 294
 in SLE, 302
Kingella kingae infectious arthritis, 557
 Kininogen, MSU crystals and, 775
Klebsiella, ankylosing spondylitis, HLA-B27 and, 1460

L

L cells, IgM, rosette formation and, 1098
 Lactate dehydrogenase in T cells in SLE, 932
 Lactic acid in synovial fluid, 1499
Lactobacillus casei-induced polyarthritis in rats, 1259
 Lead arthropathy, 1048
 Lead nephropathy, gout and, 1057
 Lectins, collagenase and, 17
 Leprosy
 osteonecrosis and, 1152
 T8 decrease in, 1479
 Leu-3a T cell subset, in temporal arteritis, 1201
 Leukapheresis in RA, 1076
 Leukemia, chronic lymphocytic, septic arthritis and, 1409
 Leukoaggregates, intravascular, morbidity in SLE and, 630
 Leukocyte-derived proteins, induction of fibroblast proliferation by, 22
 Leukocytes
 allogeneic, in RA, after total lymphoid irradiation, 937

- Leukocytes (*cont'd*)
 fibroblasts, cell-mediated immune reactions and, 22
 in pancreatic arthritis, 127
 peripheral blood, interferons and, in SLE, 575
 tripeptide-activated, superoxide radical generation and, 82
- Leukopenia
 anti-proliferating cell nuclear antigen and, 140
 in SLE, 45
- Leukotrienes
 eicosapentaenoic acid in autoimmune nephritis in mice and, 133
 in RA, 459
- Levamisole, 356
- LEW/N rats, 1259
- Ligaments
 CPPD and intervertebral hyperostosis in Barbary ape, 682
 ossification in cervical spine, 226
 in rabbit OA, 875
- Light microscopic studies
 of active cellular pannus, 472
 in detection of calcium in synovial fluid, 191
 in Lowe's (oculocerebrorenal) syndrome, 728
- Linear scleroderma. *See also* Polymyositis-scleroderma;
 Progressive systemic sclerosis; Systemic sclerosis
 antinuclear antibodies in, 612
- Link proteins in sacral cartilage, 887
- Lip biopsy in Sjögren's syndrome in scleroderma, 500
- Lipase in pancreatitis, 121
- Lipid enzymes, fat necrosis and, in pancreatitis, 121
- Lipoprotein, dietary fat and, 1532
- Lipoxygenase, benoxaprofen, proteoglycan synthesis and, 771
- Liver diseases, anticentromere antibodies in, 914
- Liver function abnormalities, proquazone and, 1288
- Liver toxicity of NSAID, 206
- Localized polyarthritis, 319
- Localized scleroderma, antinuclear antibodies in, 612
- Locomotor abnormalities, in thalassemia minor, 1292
- Low back pain, 240, 365. *See also* Backache
 sacroiliac joints and, 760
 socioeconomic impact of, 901
- Lowe's (oculocerebrorenal) syndrome, arthropathy of, 728
- Lumbar spinal stenosis, 366
- Lumbar spine
 in ankylosing spondylitis, 227
 vertebral ankylosis, CPPD and, in Barbary ape, 683
- Lung
 in chronic interstitial disease, 609
 in connective tissue diseases, 604
 in SLE, 303
- Lung disease
 after pulse therapy in RA, 1269
 rheumatoid, after total lymphoid irradiation in RA, 937
- Lung scans, ⁶⁷gallium, in progressive systemic sclerosis, 969
- Lupus diathesis, familial in males, 39
- Lupus erythematosus. *See* Systemic lupus erythematosus
- Lupus nephritis, steroids and, 637
- Lupus screening questionnaire, 692
- Lupus-like syndrome during nomifensine therapy, 936
- Lyme arthritis, 265
- Lymphadenopathy, neonatal onset multisystem inflammatory disease and, 668
- Lymphapheresis in 1419
- Lymphoblasts, phytohemagglutinin activated, Ia ALA and, 486
- Lymphocyte activating factor in joint fluid, 978
- Lymphocyte diapedesis, 1427
- Lymphocytes, 247
 ELISA detection of anti-SS-B antibodies in, 146
 in gastric mucosa in Sjögren's syndrome, 1196
 granular, human, 623
 HNK-1⁺ in SLE, 623
 human granular, in SLE, 623
 human peripheral blood, fibroblast proliferation and, 22
 IgM rheumatoid factor synthesis and, in RA, 1091
 leukapheresis and, 1076
 in PSS, 841
 in Sjögren's syndrome and scleroderma, 500
 in temporal arteritis, 1201
- Lymphocytic leukemia, septic arthritis and, 1409
- Lymphoid cells, receptor-bearing, 1098
- Lymphoid content of prostaglandins, 113
- Lymphoid irradiation, total
 in psoriatic arthritis, 1052
 in RA, 937
- Lymphoid malignancy, natural killing activity and, in Sjögren's syndrome, 954
- Lymphoma, non-Hodgkin's, in septic arthritis, 1044
- Lymphopenia in SLE, 745
 and interferon, 1415
- Lymphoplasmapheresis for RA, 1419
- Lymphoproliferation, rheumatoid factor and, in mice, 1085
- Lysate, aspirin hydrolysis and, 541
- Lysine, hydroxylation of, type II collagen-induced arthritis and, 1245

M

- Macromolecular aggregates, benoxaprofen, proteoglycan synthesis and, 771
- Macrophage chemotaxis, medullasin and, 1002
- Macrophage-like cells, cartilage destruction and, 472
- Macrophages, 248
 medullasin in granulocytes in inflammation and, 1002
 synovial fluid, in polyarthritis, 816
- Maculopapular rash, neonatal, 668
- Major histocompatibility complex, rheumatoid factor and, in mouse, 1085
- Malignancy
 bladder, cyclophosphamide in RA and, 804
 lymphoid, in Sjögren's syndrome, 954
- Malignant fibrous histiocytoma, protrusio acetabuli in, 1516

- Malignant hyperthermia, 342
- Malignant visceral scleroderma
 erosive OA in, 1041
 lack of Raynaud's phenomenon or skin involvement in, 1041
- Malnutrition in RA, 1532
- MB antigens in SLE, 1534
- McLeod syndrome, confusion with polymyositis, 806
- Median nerve entrapment, 337
- Mediastinal fibrosis, 1292
 familial, seronegative spondylarthropathy and, 221
- Medical terminology, 1176
- Medication usage in rheumatic diseases, 1017
- Medullasin in granulocytes in inflammation, 1002
- Menhaden oil, autoimmune nephritis in mice and, 133
- Meningococcal arthritis, pseudogout and, 1409
- Menisectomy
 lateral, antirheumatic drugs in rabbit OA, 1132
 in rabbit OA, 875
- Meniscus
 CPPD and vertebral hyperostosis in Barbary ape, 682
 glycosaminoglycan in beagle OA, 69
 in rabbit OA, 875
- Mesangial IgM nephropathy in HLA-B27 spondylarthropathy, 1056
- Metabolic defects in Lowe's (oculocerebrorenal) syndrome, 728
- Metabolic myopathies, 341
- Metabolic studies in RA, 294
- Metal-dependent collagenolytic activity in human OA cartilage, 63
- Metalloproteases in dog OA, 866
- Metalloproteinases in rabbit articular cartilage, 984
- Metastatic disease, protrusio acetabuli in, 1516
- Methotrexate
 gynecomastia and, 691
 in RA
Pneumocystis carinii pneumonia and, 1291
 pulse therapy, 1269
 toxicity, 119
- Methyl prednisolone
 intraarticular, skin rash after in RA, 231
 seizure after pulse therapy with, 117
- Microsars, type II collagen-induced arthritis and, 1245
- Microscopy
 capillary, in eosinophilic fasciitis, 617
 transmission electron, in type II collagen-induced arthritis, 1249
- Milwaukee shoulder, crystals in, 1220
- Mithramycin in Paget's disease, 282
- Mitogens, fibroblast proliferation and, 22
- Mixed connective tissue disease, 316. *See also* Connective tissue disease; Overlap syndrome; Undifferentiated connective tissue disease
 antibodies to Sm and RNP in, 848
 antilymphocytic antibodies in, 1535
- Mixed connective tissue disease (*cont'd*)
 antilymphocytotoxic antibodies in, 570
 anti-proliferating cell nuclear antigen and, 140
 serotonin content of platelets in, 532
- Mixed lymphocyte reaction in RA, after total lymphoid irradiation, 937
- Modified Health Assessment Questionnaire, 1346
- MOLT4 Ia negative human cell line, in RA, 486
- Monarticular arthritis, herpes zoster and, 236
- Monarticular disease in histoplasmosis epidemic, 1065
- Monoclonal antibodies
 anti-Ia, lymphoblasts and, 486
 83c2, 1187
 cell identification
 in rheumatoid nodules, 1333
 in synovial tissue, 1321
 in gastric mucosa in Sjögren's syndrome, 1196
 HNK-1⁺, 623
 human articular cartilage and, 1187
 in SLE, 745
- Monoclonal antibody (HNK 1-Leu 7) defined lymphoid cells, in RA, 1173
- Monocyte chemotactic factor production, 1449
- Monocyte-derived factor, rheumatoid synovial cells and, 8
- Monocytes, 248
 in Felty's syndrome, 947
 Ia antigens, articular cartilage and, 1187
 interleukin-1 and, 975
 peripheral blood, 1099
 in temporal arteritis, 1201
- Monocytic arthritis, chronic, 674
- Mononuclear cell infiltrates in gastric mucosa in Sjögren's syndrome, 1196
- Mononuclear cells
 α -interferon and RF synthesis, 1091
 leukapheresis in RA and, 1081
 natural killer activity in Sjögren's syndrome and, 954
 after total lymphoid irradiation, 937
- Mononuclear leukocyte-derived proteins, 22
- Mononucleosis, infectious, symmetric polyarthritis and, 553
- Monosodium urate (MSU) crystals
 in asymptomatic joints, 1522
 plasma protein binding and, 775
- Moonshine ingestion, gout and, 1057
- Moraxella infections, 557
- Morning fatigue in fibrositis, 817
- Morning stiffness in RA, 937
 penicillamine and, 581
- Morphea, antinuclear antibodies in, 612
- Mortality rates for polymyositis and dermatomyositis, 1465
- Moth-eaten mice, 257
- Mouse studies. *See* Animal models
- MRL/l mice, 256, 645
- MRL/MpJ-1pr mice, 1085
- MRL/Mp-1pr/1pr mice, 645
- MRL/n mice, 256, 645

MSU. *See* Monosodium urate
 MT antigens, autoantibody expression in SLE, 1533
 Mucopolysaccharidoses (MPS), 245
 Multicentric reticulohistiocytosis, synovial microvasculature in, 1427
 Multiple myeloma, protrusio acetabuli in, 1516
 Multiple sclerosis, T8 decrease in, 1479
 Murine lupus
 cyclophosphamide in, 1293
 dietary fat and, 1532
 hypertension in, 1340
 Muscle, 341
 Muscle atrophy in polymyositis and dermatomyositis, 961
 Muscle disease
 anti-Jo-1 antibody in, 608
 creatine kinase in diagnosis of, 201
 Muscle strength, DMSO, sulindac and, 791
 Muscle weakness, creatine kinase and, in amyotrophic lateral sclerosis, 201
 Musculoskeletal diseases
 diagnosis of, 241
 socioeconomic impact of, 901
 Musculoskeletal involvement in fibrositis, 817
 Mycobacterial arthritis, 265
Mycoplasma hominis, septic arthritis due to, 1044
 Myocardial infarcts in murine lupus, 1340
 Myofascial pain disorders, 337
 Myokemia, as complication of gold therapy, 825
 Myositis, esophageal symptoms in, 961

N

Nailfold capillary microscopy
 in childhood dermatomyositis, 1169
 in eosinophilic fasciitis and scleroderma, 617
 Naproxen, 350
 hemolytic anemia and, 1054
 National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases, 548
 Native DNA
 antibodies to, enzyme immunoassay for, 52
 platelet release reaction and, 179
 Native IgM, binding of, to Fc receptors for IgG, 1098
 Natural killer cells
 assay for, 1317
 dietary fat and, 1532
 interferon and, 1452
 in Sjögren's syndrome, 954
 in SLE, 623, 1316, 1452
 NDA. *See* New Drug Application
 nDNA. *See* Native DNA
Neisseria meningitidis in septic arthritis, 1409
 Neonatal lupus erythematosus, 304
 HLA-DR3 in, 210
 Neonatal onset multisystem inflammatory disease, 668
 Neoplastic diseases, protrusio acetabuli in, 1512, 1515
 Nephritis. *See also* Glomerulonephritis; Nephropathy; Oculocerebrorenal; Renal
 autoimmune, dietary eicosapentaenoic acid in mice and, 133
 Nephropathy
 acute oliguric tubulointerstitial, after fenoprofen in RA, 234
 in ankylosing spondylitis, 816, 930
 lead, gout and, 1057
 mesangial IgM, HLA-B27 spondylarthropathy and, 1056
 Nephrotic syndrome
 gold in the elderly and, 705
 SLE associated, protein/creatinine ratios in, 919
 Neural lesions, protective effect of on RA, 118
 Neuroblastoma cells, cytotoxicity in scleroderma and, 170
 Neurofibromatosis, in SLE, 574
 Neurologic complications
 of gold therapy, 825
 in systemic sclerosis, 313
 Neuromuscular disturbances, in RA, 293
 Neuropathy
 complication of gold therapy, 825
 in lead arthropathy, 1048
 peripheral
 after concomitant DMSO and sulindac, 791
 hyperuricemia and, in gout, 1057
 Neurovascular entrapment disorders, 336
 Neutral proteinases in rabbit articular cartilage, 984
 Neutropenia
 dialysis-induced, neutrophil aggregation in SLE and, 630
 of Felty's syndrome, bone marrow-directed immune mechanisms, 947
 Neutrophils
 aggregation in SLE, 630
 temporal arteritis and, 1201
 in type II collagen-induced arthritis, 1120
 New Drug Application (NDA), 1355
 New Zealand mice, 253
 Nifedipine
 in digital ulceration in scleroderma, 809
 for pulmonary hypertension in systemic sclerosis, 794
 Nitritoid reaction, 1310
 Nodosum leprosum eruption, T8 decrease and, 1479
 Nodules
 rheumatoid, ultrasound diagnosis of, 696
 subcutaneous
 in gout in Heberden's nodes, 94
 in pancreatitis, 121
 in RA, HLA antigens and, 1053
 tophaceous, ultrasound diagnosis of, 696
 Nomifensine, lupus-like syndrome and, 936
 Nonarticular gout, hyperuricemia and tophus without gouty arthritis in, 98
 Nonarticular rheumatism, 335
 Non-Hodgkin's lymphoma in *M hominis* septic arthritis, 1044

Nonosseous calcifications, 283
 Nonsteroidal antiinflammatory drugs, 345
 aspirin and, 1288
 benoxaprofen and proteoglycan synthesis, 771
 coagulation and, 348
 drug trials for, 1358
 gastrointestinal side effects of, 347
 glycosaminoglycan metabolism in articular cartilage and, 528
 in histoplasmosis, 1065
 intraarticular use, 1380
 liver toxicity of, 206
 "not for initial therapy" (FDA), 1288
 prostaglandins and, 347
 in RA, 937
 in rabbit OA, 1132, 1380
 renal effects of, 348
 serotonin content of platelets and, 532
 terminology of, 1415
 Nordihydroguaiaretic acid, glycosaminoglycan synthesis and, 771
 NSAID. *See* Nonsteroidal antiinflammatory drugs
 Nuclear antigens
 antikeratan antibodies and, 494
 rheumatoid arthritis (RANA), 712
 Nuclear protein, antibodies to, anti-Sm and, 848
 Nuclear protein antigen, acidic, in connective tissue diseases, 604
 Nude mice, 257
 Nutritional status
 in autoimmune diseases, 1532
 in RA, 462, 1532
 NZB/NZW mice, 113, 645
 NZB \times NZW/F₁ mice, 133

O

Obesity, urate clearance and, in gout, 1057
 Obturator nerve compression, 337
 Ochronosis, 344
 CPPD deposition and, 1387
 Octacalcium phosphate in human synovial fluid, 1220
 Ocular disease
 in MRL mice, 645
 vasculitis, 322
 Oculocerebrorenal (Lowe's) syndrome, arthropathy of, 728
 OKM1 antibodies
 in rheumatoid nodule cells, 1333
 in synovitis, 1321
 OKT antibodies
 in rheumatoid nodule cells, 1333
 in synovitis, 1321
 OKT3 antibodies
 in Sjögren's syndrome, 1196
 in SLE, 623
 OKT4 antibodies
 in PSS, 841
 in Sjögren's syndrome, 1196
 in SLE, 745
 OKT8 antibodies
 in polymyalgia rheumatica, 1472
 in PSS, 841
 in SLE, 745
 Olecranon bursitis, CPPD deposition disease and, 695
 Oligoarticular disease in histoplasmosis epidemic, 1065
 Orgotein in rabbit OA, 1132, 1382
 Orphan drugs, 206
 Orthopedic surgery, 359
 Ossification
 intersternocostoclavicular, 784
 posterior longitudinal ligament, in cervical spine, 226
 Osteitis condensans ilii in apatite crystal deposition disease, 567
 Osteoarthritis, 278. *See also* Degenerative joint disease
 alizarin red S staining in, 191
 amyloid deposits and, 120
 articular cartilage collagen, proteoglycans and, 1111
 cartilage
 effect of aspirin on, 994
 polymorphonuclear leukocytes in, 1436
 collagen in cartilage of dog model of, 866
 collagenase and collagen in cartilage in, 63
 erosive, gout in Heberden's nodes and, 94
 in PSS, 1041
 gout in Heberden's nodes and, 96
 gouty arthritis in, 94
 interleukin-1-like factor in, 975
 mononuclear cell-stimulated synovial cells in, 15
 national impact of, 905
 natural, glycosaminoglycans in menisci in, 69
 osteophytes in, 908
 protrusio acetabuli in, 1513
 rabbit model of, 875, 1132, 1380
 secondary, epiphysiolysis and, 910
 with RA, 912
 socioeconomic impact of, 901
 synovial fluid
 immune complexes in, 156
 lactic acid in, 1500
 synovial microvasculature in, 1427
 "tilt deformity" in, 909
 treatment of, 280
 intraarticular drugs, 1380
 Osteochondritis dessicans, 285
 Osteochondromatosis, 285
 Osteogenesis imperfecta, protrusio acetabuli in, 1516
 Osteomyelitis
 in children, 262
 pyarthrosis and, "cocktail sausage" digit in, 664
 Osteonecrosis
 of femoral head, 913
 in pancreatitis, 129

Osteophyte formation in rabbit OA, 875
 Osteophytes
 in CPPD disease and vertebral hyperostosis, 685
 in OA, 908
 Osteopetrosis, 283
 Osteoporosis, 284
 Otto's pelvis, 1511
 Outcome measurements, patient, 697
 Overlap syndrome. *See also* Connective tissue disease;
 Mixed connective tissue disease; Undifferentiated con-
 nective tissue disease
 anti-Jo-1 antibody in, 604

P

Paget's disease of bone, 281
 and gout in SLE, 238
 protrusion acetabuli in, 1515
 Pain
 axial, in fibrositis, 817
 chronic persistent, 340
 health status and behavior and, 1017
 interphalangeal, video games and, 120
 low back. *See* Backache; Low back pain
 myofascial, disorders of, 337
 relief of, in juvenile arthritis, 1140
 in rheumatic diseases, 1017
 in tuberculosis of greater trochanteric bursa, 77
 Pain threshold in fibrositis, 817
 Palmerston North mice, 257, 645
 Palosein, in rabbit OA, 1382
 Pan-American Congress of Rheumatology, involvement of
 pharmaceutical companies at, 239
 Pan-American League Against Rheumatism, 578
 Pancreatic arthritis, free fatty acids in, 127
 Pancreatitis
 with arthropathy and subcutaneous fat necrosis, 121
 fat necrosis and arthritis in, 127
 in SLE, 238, 1173
 Pannus. *See also* Cartilage-pannus junction
 active cellular, light and electron microscopic studies of,
 472
 RANA and EBV antigens in RA, 712
 Paralysis
 brachial, in giant cell arteritis, 207
 in RA, 118
 Paramethasone in rabbit OA, 1132, 1380
 Parasitic arthritis, 265
 Patellofemoral joint space, CPPD disease, vertebral hyper-
 ostosis and, 684
 Patient assessment
 of activities of daily living, 1346
 penicillamine and, in RA, 581
 in rheumatic diseases, 241, 1017
 Patient examination skills, 658
 Patient outcome measurement, 697
 Pauciarticular disease in juvenile arthritis, 1208
 Pauciarticular onset juvenile arthritis, HLA antigens in, 35
 Penicillamine, 355
 IgG and IgM rheumatoid factors in RA and, 593
 in penicillin-sensitive patients, 801
 in RA, 581, 937
 in rabbit OA, 1132
 toxicity of, 581
 Penicillin, structure of, 802
 Pentosan polysulfate, in rabbit OA, 1382
 Pericarditis, in SLE with Reiter's syndrome, 1405
 Pericellular matrix, human articular cartilage and, 1187
 Periosteal new bone formation in pancreatic arthritis, 129
 Peripheral neuropathy
 after DMSO and sulindac, 791
 in hereditary amyloidosis, 1494
 hyperuricemia and in gout, 1057
 Phagocytosis
 effect of gold compounds on, 82
 inflammation and, 252
 Pharmaceutical companies, involvement at Pan-American
 Congress of Rheumatology, 239
 Pharmaceutical conferences, value of, 695
 Phase III drug trials, 1354
 Phenacetin, 352
 Phenylbutazone in rabbit OA, 1382
 Phenytoin in RA, 118
 Phospholipase A in pancreatitis, 121
 Phosphoribosyl pyrophosphate synthetase, 267
 Physical disability as predictor of pain in rheumatic diseases,
 1017
 Physician assessment
 in RA, 581
 in rheumatic diseases, 1017
 Pirofen in rabbit OA, 1132, 1382
 Placebo controlled drug trials, 1355
 Placebo versus auranofin and gold sodium thiomalate, 1303
 Plasma cells in gastric mucosa in Sjögren's syndrome, 1196
 Plasma protein binding by monosodium urate crystals, 775
 Plasmapheresis for RA, 1419
 Plasminogen activator, mononuclear cell-stimulated synovi-
 al cells and, 15
 Platelets
 blood, inorganic pyrophosphate in, 564
 penicillamine and in RA, 587
 serotonin content of in inflammatory rheumatic diseases,
 532
 Plethysmography, finger, in Raynaud's phenomenon, 1177
 Pleuropericarditis, anti-proliferating cell nuclear antigen
 and, 140
 PMN. *See* Polymorphonuclear leukocytes
 PMR. *See* Polymyalgia rheumatica
 Pneumarthrosis, in *Serratia liquefaciens* infection, 1166
 Pneumococcal pyarthrosis, joint, chemotactic defect and,
 1160
Pneumocystis carinii pneumonia in RA, 1275

- Pneumonia preceding meningococcal arthritis, 1409
- Poliomyelitis, seropositive nodular, RA after, 118
- Polyarteritis, localized, 319
- Polyarteritis nodosa, 319
- ruptured intrahepatic aneurysm and, 106
- Polyarthritis
- collagen and, 694
 - Lactobacillus casei*-induced in rats, 1259
 - neonatal onset multisystem inflammatory disease and, 668
 - in rats, 1120
 - seronegative
 - pyoderma gangrenosum and, 813
 - synovial tissue cells in, 1321
 - streptococcal cell wall-induced in rats, 560, 1442
 - symmetric, infectious mononucleosis and, 553
 - synovial fluid macrophages in, 816
 - synovial microvasculature in, 1427
 - in undifferentiated connective tissue disease, 1160
- Polyarticular onset juvenile arthritis, HLA antigens and, 35
- Polychondritis, relapsing, 285
- Polyinosinic acid, ³H-serotonin release and, 179
- Polymorphonuclear leukocytes (PMN)
- interaction with immune complexes, 1434
 - tripeptide-activated, superoxide radical generation and, 82
- Polymyalgia, synovial fluid lactic acid in, 1500
- Polymyalgia rheumatica
- ARA criteria for RA and, 1417
 - circulating immune complexes in, 1472
 - dapsone in, 689
 - HLA-DR3 and DR4 in, 925
 - T cell subsets in, 1472
 - temporal arteritis and, 1472
- Polymyositis, 316. *See also* Dermatomyositis
- amyotrophic lateral sclerosis and, 201
 - anti-Jo-1 antibody in, 604
 - confusion with McLeod syndrome, 806
 - dysphagia, and esophageal abnormalities in, 961
 - fibrosis in, 961
 - interstitial pulmonary fibrosis, Jo-1 antigen and, 604
 - mortality in the U.S. from, 1465
- Polymyositis-dermatomyositis, 606. *See also* Dermatomyositis
- Polymyositis-scleroderma, 604. *See also* Dermatomyositis; Progressive systemic sclerosis; Scleroderma; Systemic sclerosis
- Polymyositis-systemic lupus erythematosus syndrome, 604. *See also* Central nervous system lupus; Cutaneous lupus; Dermatomyositis; Drug-induced lupus; Lupus; Neonatal lupus; Systemic lupus erythematosus
- Polynucleotides, aggregated IgG-induced ³H-serotonin reaction and, 183
- Polypeptide growth factors, 1370
- Polypeptides
- immunoreactive, anti-SS-B antibodies and, 146
 - plasma protein binding by MSU crystals and, 775
- Polyradiculoneuritis, T cell subsets in, 1479
- Pond-Nuki dog model of OA, 866
- Popliteal cysts, 344
- Post bypass arthropathy, 328
- Post intestinal bypass arthritis, effect of intestinal bypass revision on, 678
- Prealbumin in Indiana type hereditary amyloidosis, 1493
- Prednisolone, skin rash after in RA, 231
- Prednisone
- in McLeod syndrome, 806
 - in SLE, 745
 - testosterone oxidation and, 1517
- Pregnancy
- ankylosing spondylitis and, 1155
 - RA and, 1155
 - SLE and, 304
- Primary biliary cirrhosis, anticentromere antibodies in, 914
- Primary sicca syndrome, anti-SS-B antibodies and, 146
- Progressive systemic sclerosis. *See also* Polymyositis-scleroderma; Scleroderma; Systemic sclerosis
- antibodies to Sm and RNP in, 848
 - articular presentation of, 1041
 - capillary microscopy in eosinophilic fasciitis and, 617
 - cytotoxicity of sera in, 170
 - ⁶⁷gallium lung scans in, 969
 - serotonin content of platelets in, 532
 - serum antibodies in, 505
 - Sjögren's syndrome in, 500
 - skin in, 653
 - T cells in, 841
- Proliferative villus synovitis in rats, 1259
- Propranolol in murine lupus, 1341
- Propionic acid derivatives, benoxaprofen, proteoglycan synthesis and, 771
- Proquazone, 1288
- Prostacyclin production and inhibition, 1300
- Prostaglandin E and diet in RA, 459
- Prostaglandin E₂
- indomethacin and, 8
 - rheumatoid synovial cells and, 8
 - in streptococcal cell wall-induced polyarthritis, 1449
 - transforming growth factors and, 1374
- Prostaglandin F in mice, 115
- Prostaglandins
- eicosapentaenoic acid in autoimmune nephritis in mice and, 133
 - hypothetical action of, 1300
 - inflammation and, 252
 - lymphoid tissue content in mice, 113
 - NSAID and, 347
 - in Sjögren's syndrome, 954
- Protease
- medullasin, in inflammation, 1002
 - in pancreatitis, 121
 - vascular permeability and, 1008
- Protein
- benoxaprofen and, 771

- Protein (*cont'd*)
 binding by monosodium urate crystals, 775
 core, CTAP and, 522
 in dermal-epidermal junction in SLE, 1294
 fibrin and fibronectin in RA, 479
 induction of fibroblast proliferation by, 22
 link, in sacral cartilage, 887
 SS-B, anti-SS-B antibodies and, 146
- Protein/creatinine ratio in SLE associated nephrotic syndrome, 919
- Proteinase
 cartilage, in rabbit articular cartilage, 984
 mononuclear cell-stimulated synovial cells and, 15
- Proteinase inhibitors
 in pancreatitis, 121
 in rabbit cartilage, 991
- Proteinuria
 in autoimmune nephritis in mice, 136
 in SLE, 918
- Proteoglycans, 244
 catabolism of, 771
 CTAP and, 522
 enzyme hydrolysis studies of, 522
 in extracellular matrix, 528
 in hereditary chondrocalcinosis, 1395
 metalloproteinases in rabbit articular cartilage and, 984
 rabbit articular proteinases and, 989
 in sacral cartilage, 887
 synovial, ^{14}C -amino acid, $^{35}\text{SO}_4$ incorporation and, 527
 synthesis
 aspirin and, in canine OA cartilage, 994
 benoxaprofen and, 771
 in chondrocytes, 1225
 in human synovial cells, 522
 by PSS fibroblasts, 1366
 in type II collagen-induced arthritis, 1237
- Protrusio acetabuli, 1511
- Proximal esophageal skeletal muscle dysfunction, polymyositis, dermatomyositis and, 961
- Pseudoallergic monarticular arthritis, 1416
- Pseudoarthrosis, spinal fractures in ankylosing spondylitis and, 754
- Pseudogout, 277. *See also* Calcium pyrophosphate dihydrate deposition disease; Chondrocalcinosis
 septic arthritis and, 1409
 synovial fluid lactic acid in, 1500
- Pseudomonas aeruginosa*, septic arthritis and, 1500
- Psoriasis, synovial tissue cells in, 1321
- Psoriatic arthritis, 328
 interleukin-1-like factor in, 975
 lateral subluxation of cervical spine in, 109
 pregnancy and, 1156
 serum antibody reactive with human stratum corneum in, 494
 total lymphoid irradiation in, 1052
- Psoriatic lesions of elbow, 785
- PSS. *See* Progressive systemic sclerosis
- Psychological disability as predictor of pain, 1017
- Public perceptions and misperceptions of arthritis, 1023
- Pulmonary arterial endothelial cells, cytotoxicity of in scleroderma, 170
- Pulmonary disease in systemic sclerosis, 312
- Pulmonary fibrosis, interstitial, with polymyositis, Jo-1 antigen and, 604
- Pulmonary hypertension
 nifedipine for in systemic sclerosis, 794
 vascular reactivity and, in systemic sclerosis, 1037
- Pulmonary involvement
 in RA, 293
 in SLE, 303
- Pulse therapy
 acute lung disease after in RA, 1269
 seizure after with methyl prednisolone, 117
 in SLE, central nervous system after, 809
- Purified anticollagen immunoglobulin, type II collagen-induced arthritis and, 1120
- Purine metabolism, 266
- Purine nucleoside phosphorylase, 269
- Pustular plantar lesions in sternocostoclavicular hyperostosis, 788
- Pustulotic arthroosteitis, 784
- Pyarthrosis
 joint pneumococcal, chemotactic defect and, 1160
 osteomyelitis and, "cocktail sausage" digit in, 664
- Pyogenic arthritis, PMN in cartilage of, 1436
- Pyoderma gangrenosum, seronegative erosive polyarthritis and, 813
- Pyrophosphate, CPPD crystal deposition disease and, 564
- ## Q
- Quackery in arthritis, 1023
- Quadriceps tendons, calcification of, CPPD disease, vertebral hyperostosis and, 684
- Quantitative sacroiliac scintigraphy, in ankylosing spondylitis and Reiter's disease, 217
- Questionnaire, Modified Health Assessment, 1346
- ## R
- Rabbit studies, 127, 875, 1132
- Race
 anti-RNP antibodies and, 509
 giant cell arteritis and, 1214
- Radiation therapy linked to protrusio acetabuli, 1516
- Radical synovectomy in lead arthropathy, 1048
- Radiculopathy, cervical, in giant cell arteritis, 207
- Radiotherapy in RA, 937
- Raji cells, steroids, immune complexes and, in SLE, 637
- RANA. *See* Rheumatoid arthritis nuclear antigen
- Range of motion in juvenile arthritis, 1140
- Rash
 maculopapular, neonatal, inflammation and, 668

Rash (*cont'd*)

skin, after intraarticular methyl prednisolone in RA, 231
in SLE, 745

Rat studies, 815, 861, 1120, 1237

Raynaud's phenomenon, 315

antibodies to Sm and RNP in, 848

nifedipine in, 1177

Reassociation kinetics, EBV genomes and, in RA, 717

Rebound phenomenon after lymphoplasmapheresis, 1422

Red meat in RA, 462

Reflex sympathetic dystrophy, 337

Rehabilitation of hip in juvenile arthritis, 815

Reiter's syndrome, 325

ankylosing spondylitis and, 1463

"cocktail sausage" digit in, 664

HLA-B27 and, 1460, 1463

interleukin-1-like factor in, 975

SLE and, 1405

synovial fluid lactic acid in, 1500

synovial microvasculature in, 1427

Relapsing polychondritis, 285

Remission in RA, definition, 1305

Remittive agents in eighteenth century medicine, 935

Renal crisis in scleroderma after captopril, 797

Renal disease

ankylosing spondylitis and, 930

anti-Sm and, 848

dietary eicosapentaenoic acid and, 133

rheumatic disease and, 345

in systemic sclerosis, 313

Renal failure

acute, after fenoprofen in RA, 234

after captopril, 797

alizarin red S staining in, 191

CPPD deposition and, 1387

monosodium urate crystals and, 1523

Renal function

captopril and, 799

lead excretion and, in gout, 1061

NSAID and, 348

urate and, 271

Renal involvement

in gout with coexistent RA, 98

in SLE, temporomandibular joint arteritis and, 1508

Renal stones in gout, 274

Rengasil in rabbit OA, 1382

Reproductive tract in SLE, 304

Respiratory burst, gold compounds and, 82

Respiratory distress syndrome, adult, in SLE, 630

Retinoic acid, synovial cells and, 15

Retinoids and cell growth, 1376

Retinol binding protein

in hereditary amyloidosis, 1493

in RA, 1532

Retroperitoneal fibrosis, seronegative spondylarthropathy
and, 221

Rheumatic diseases

antibodies against ribonucleoprotein particles and, 509

antibodies to collagen in, 832

antibodies to Sm and RNP in, 848

anticollagen antibodies in, 832

antikeratin antibodies in, 494

anti-proliferating cell nuclear antigen and, 140

artist's depiction of, 1266

chronic monocytic arthritis in, 674

community hospital and, 1033

cytotoxicity and, 170

diet in, 462

etiology of, 551

inflammatory, serotonin contents of platelets in, 532

pain in, 1017

patient satisfaction in activities of daily living, 1346

Rheumatic fever, 333

Rheumatism, soft tissue fibrositis, 817

Rheumatoid arthritis nuclear antigen (RANA) in RA, 712

Rheumatoid arthritis (RA), 290. *See also* Felty's syndrome;

Juvenile arthritis

albumin in, 587

alizarin red S staining in, 191

allogeneic leukocytes in, after total lymphoid irradiation,
937

androgen plasma in females, 935

anemia and, 28

antibodies to collagen in, 832

antibodies to Sm and RNP in, 848

antibody/DNA complexes in, 736

anti-Fab' antibodies, 1481

antiinflammatory drugs in, 298

antikeratin antibodies in, 494

antilymphocyte antibodies in, 486

antinuclear antibodies and total lymphoid irradiation in,
944

anti-OKT monoclonal antibodies in, 486

anti-proliferating cell nuclear antigen and, 140

ARA criteria for, and polymyalgia rheumatica, 1417

articular manifestations of, 291

aspirin in, 937

auranofin for, 1303

beclomethasone dipropionate for, 1412

bladder malignancy and cyclophosphamide in, 804

cardiac lesions in, 293

cell-mediated immunity in, 296

clinical studies of, 290

coexistent gout and, 98, 275

collagen in, antibodies to, 832

concanavalin A in, after total lymphoid irradiation, 937

course and prognosis of, 292

cyclophosphamide in, bladder malignancy and, 804

cytotoxic cells after total lymphoid irradiation in, 937

diet in, 457, 1532

disease activity in, IA specific ALA and, 486

disease suppressive therapy in, 296

Rheumatoid arthritis (*cont'd*)

- drug studies in, 1303
- epidemiology of, 290
- Epstein-Barr virus antigen in, 712
- erosions and HLA antigens in, 1053
- erythrocyte sedimentation rate in, 593
- erythrocytes in, 736
- erythropoiesis and, 28
- extraarticular features of, 292
- fatigue after total lymphoid irradiation, 937
- Felty's syndrome in, after total lymphoid irradiation, 937
- fibrin and fibronectin in synovial membrane and fluid in, 479
- functional ability in, 937
- gastrointestinal disease in, 294
- globulin in, 587
- gold compounds and superoxide generation in, 82
- gold therapy for, 705, 937, 1071, 1303
- gold toxicity in, 1074
- growth factors in, 1370
- helper cells after total lymphoid irradiation in, 937
- hematocrit in, 587
- hematologic studies of, 294
- HLA antigens and, 1053
- human alpha-interferon in, 1091
- Ia antigens in cartilage and, 1187
- Ia negative human cell line (MOLT4) in, 486
- Ia positive human cell line (B35M0) in, 486
- Ia specific antilymphocyte antibodies in, 486
- IgG in, 836
 - Ia specific antilymphocyte antibodies and, in, 486
 - total lymphoid irradiation and, in, 943
- IgG rheumatoid factor in, 593
- IgM in, 28
 - Ia specific antilymphocyte antibodies and, in, 486
 - total lymphoid irradiation and, in, 943
- IgM rheumatoid factor in, 593
 - synthesis of, in, 1091
- immune complexes in, 156
- immunogenetics of, 297
- immunoglobulin synthesis after total lymphoid irradiation, 937
- immunopathology of, 296
- infection and, 295
- interleukin-1-like factor in, 975
- intestinal isoenzyme of alkaline phosphatase in, 574
- joint scores in, penicillamine and, 593
- joint swelling in, 581, 937
- joint tenderness in, 937
- joint-restricted, beta-2-microglobulin in, 721
- kidney in, 294
- laboratory studies in, 291
- leukapheresis in, 1076
- leukotrienes in, 459
- lymphoplasmapheresis for, 1419
- metabolic studies of, 294

Rheumatoid arthritis (*cont'd*)

- methotrexate pneumonia in, 1275
- methotrexate toxicity in, 119
- mixed leukocyte reaction in, after total lymphoid irradiation, 937
- monoclonal antibodies in, 1173
 - anti-Ia, 486
- mononuclear cell-stimulated synovial cells in, 15
- morning stiffness in, 937
- national impact of, 905
- neuromuscular disturbances in, 293
- neutrophil aggregation in, 630
- nodules, subcutaneous in, 292
- NSAID in, 937
- pathogenesis of, 295
- patient assessment and penicillamine in, 581
- patient satisfaction in activities of daily living, 1346
- penicillamine in, 581
- peripheral blood lymphocytes and total lymphoid irradiation, 942
- Phase III drug trials in, 1354
- phenytoin in, 118
- physician assessment in, 581
- phytohemagglutinin after total lymphoid irradiation in, 937
- platelets in, 587
- PMN and immune complex interaction in, 1434
- Pneumocystis carinii* pneumonia after methotrexate in, 1291
- pregnancy and, 1155
- prognosis and course of, 292
- prostaglandin E in, 459
- protective effect of neural lesion on, 118
- protrusio acetabuli in, 1512
- pulmonary complications of, 293
- pulse therapy in, 1269
- radiographic assessment of, 291
- radiotherapy in, 937
- RANA in, 712
- renal failure after fenoprofen, 234
- rheumatoid factor and, 28, 593, 1053
 - total lymphoid irradiation in, 944
- rheumatoid lung disease after total lymphoid irradiation in, 937
- secondary amyloidosis, diagnosis of by endometrial biopsy in, 1295
- with secondary OA, 912
- seronegative, B7-CREG in, 1412
- seropositive, DMSO and, 693
- serotonin content of platelets in, 532
- serum copper in, 933
- serum zinc in, 933
- skin in, 292
- socioeconomic impact of, 901
- steroid drugs after total lymphoid irradiation in, 937
- streptococcal cell wall-induced model of, 1442

- Rheumatoid arthritis (*cont'd*)
 subcutaneous nodules in, 292
 identification of, 1333
 suppressor cells after total lymphoid irradiation in, 937
 surgery in, 300
 synovectomy, nonsurgical, in, 300
 synovial biopsy in, 291
 synovial fluid in, 290
 lactic acid in, 1499
 synovial microvasculature in, 1427
 synovial tissue cells in, 1321
 synovial tissue proliferation in, 1370
 T8 decrease in, 1478
 therapeutic response in, 1305
 total lymphoid irradiation in, 937
 treatment of, 297
 walking time in, D-penicillamine and, 581
 wine treatment of skin ulcerations in, 934
- Rheumatoid arthritis precipitin in connective tissue diseases and PSS, 505
- Rheumatoid factor, 250
 anemia in RA and, 28
 effect of depletion of, on anti-SS-B binding, 152
 genetic control of, in mice, 1085
 IgG2a-specific, in mice, 1085
 IgM rheumatoid factor
 effect of on rosette formation, 1098
 immune complexes and, in juvenile arthritis, 165
 synthesis of in RA, 1091
 immune complexes and, in RA, 160
 Lowe's (oculocerebrorenal) syndrome and, 728
 in RA, 28, 593, 1053
 19S, 1053
 total lymphoid irradiation and, 944
 steroids, immune complexes and, in SLE, 637
- Rheumatoid hand in Flemish paintings, 1266
- Rheumatoid joint fluid, lymphocyte activating factor in, 978
- Rheumatoid lung disease, total lymphoid irradiation and, in RA, 937
- Rheumatoid nodules
 characterization of, 1333
 ultrasound diagnosis of, 696
- Rheumatoid synovial cells, 8
- Rheumatoid synovial cyst of hip, 814
- Rheumatoid synovial fluid
 immune complexes and, 156
 immunoprecipitates in, 483
- Rheumatologists in community hospitals, 1033
- Rheumatology
 American, 548
 classification of, 1029
 education, 241, 577, 658
 research, 550
- Rheumatology practice
 ARA nomenclature and classification of arthritis and rheumatism, 1029
- Rheumatology practice (*cont'd*)
 in community hospital, 1033
 private, in Mexico City, 688
- Rhino mice, 257
- Ribonucleic acid (RNA), antibodies, RNP particles and, 510
- Ribonucleoprotein (RNP), antibodies, 509, 848
- RNA. *See* Ribonucleic acid
- RNP. *See* Ribonucleoprotein
- Rosette formation, effect of IgM rheumatoid factor on, 1098
- S**
- Sacroiliac cartilage, 887
- Sacroiliac joint
 biochemical and morphologic studies of cartilage in, 887
 computed tomography of, 760
 scintigraphy of, 217
 in seronegative spondylarthropathy, 222
 in sternocostoclavicular hyperostosis, 787
- Sacroiliitis
 radiographic diagnosis of, 760
 SLE with Reiter's syndrome and, 1406
- Salicylate derivatives, 349
- Salicylates, 349. *See also* Aspirin
 in canine OA cartilage, 528, 994, 1234
 hydrolysis of, 541
 matrix proteoglycans, articular cartilage and, 528
- Salivary glands in Sjögren's syndrome and PSS, 500
- Sarcoidosis, 343
- Schirmer's test in Sjögren's syndrome and PSS, 500
- Schönlein-Henoch syndrome, familial Mediterranean fever and, 1536
- Scintigraphy, in ankylosing spondylitis and Reiter's disease, 217
- Scleroderma. *See also* Polymyositis-scleroderma; Progressive systemic sclerosis; Systemic sclerosis
 acroosteolysis and acronecrosis in, 1151
 anticentromere and ANA antibodies in, 1
 capillary microscopy in eosinophilic fasciitis and, 617
 connective tissue activation in, 1362
 cytotoxicity of sera in, 170
 diffuse, in primary biliary cirrhosis, 914
 anti-proliferating cell nuclear antigen and, 140
 esophageal abnormalities in polymyositis and dermatomyositis and, 961
⁶⁷gallium lung scans in, 969
 linear, antinuclear antibodies in, 612
 localized, antinuclear antibodies in, 612
 malignant visceral, articular presentation of, 1041
 nailfold capillary changes in, 617
 nifedipine for digital ulceration in, 809
 Sjögren's syndrome in, 500
 skin fibroblasts in, 1362
 synovial fluid lactic acid in, 1500
- Scleroderma renal crisis, reversal after captopril, 797

- Seizures after pulse therapy with methyl prednisolone, 117
- Septic arthritis. *See also* Infectious arthritis
 in children, 262
 diagnosis of, 1499
 due to *Mycoplasma hominis*, 1044
 pseudogout and, 1409
 synovial fluid lactic acid in, 1499
- Septic bursitis, 263
- Seronegative arthritis, anti-proliferating cell nuclear antigen in, 140
- Seronegative erosive polyarthritis, pyoderma gangrenosum and, 813
- Seronegative juvenile arthritis, HLA antigens in, 35
- Seronegative spondylarthropathy, familial mediastinal fibrosis and, 221
- Seropositive juvenile arthritis. *See* Juvenile arthritis
- Seropositive rheumatoid arthritis. *See* Rheumatoid arthritis
- Serotonin in inflammatory rheumatic diseases, 532
- Serratia liquefaciens* arthritis, 1166
- Serum amyloid A and P components, 333
- Serum hemolytic complement (CH50), antibodies to nDNA in SLE and, 52
- Serum protein binding of monosodium urate crystals, 775
- Serum transfer of collagen-induced arthritis, 1237
- Sex hormones in streptococcal cell wall-induced polyarthritis, 560
- Shoulder
 sternocostoclavicular hyperostosis and, 785
 total replacement of, 364
- Sicca syndrome, primary, anti-SS-B antibodies and, 146
- Sickle cell-thalassemia disease, tophaceous gout in, 928
- Silica crystal-associated polypeptides, protein binding and, 781
- Single-stranded DNA (ssDNA). *See* DNA
- Sjögren's syndrome, 310
 anti-SS-B antibodies and, 146
 cytotoxicity in, 954
 lymphocytes of gastric mucosa in, 1196
 natural killing activity in, 954
 in PSS, 500
- Skeletal hyperostosis
 CPPD and, in Barbary ape, 682
 diffuse idiopathic. *See* Diffuse idiopathic skeletal hyperostosis (DISH)
- Skeletal imaging in ankylosing spondylitis and Reiter's disease, 217
- Skeletal muscle dysfunction, polymyositis, dermatomyositis and, 961
- Skeletal tuberculosis, 77
- Skin
 in histoplasmosis, 1065
 in PSS, 312, 653
 in RA, 292, 1080
 rash from intraarticular prednisolone, 231
 ulcerations, treatment for, 934
- Skin biopsies in SLE, 1294
- Skin fibroblasts in scleroderma, 1362
- Sleep disturbances in fibrositis, 818
- Sm antibodies, 848
- Smooth muscle antigens in RA, 494
- Smooth muscle atrophy in polymyositis and dermatomyositis, 961
- Sodium aurothiomalate. *See also* Gold
 neurologic complications of, 825
 superoxide radical generation and, 82
- Sodium salicylate. *See also* Acetylsalicylic acid; Aspirin;
 Salicylates
 action of, 1300
 effect of, on GAG synthesis in canine OA cartilage, 999
 glycosaminoglycan synthesis and, 528
- Soft tissue injuries, 336
- Soft tissue rheumatism, 817
- SP 54 in rabbit OA, 1382
- Spinal deformity, grades of, 187
- Spinal disorders, 365
- Spinal fractures complicating ankylosing spondylitis, 751
- Spinal stenosis, 366
- Spine
 in ankylosing spondylitis, 186, 226
 cervical, 367
 ankylosing spondylitis in, 226
 lateral subluxation of in psoriatic arthritis, 109
 posterior longitudinal ligament ossification in, 226
 in seronegative spondylarthropathy, 223
 sternocostoclavicular hyperostosis and, 786
- lumbar, CPPD, vertebral hyperostosis and, in Barbary ape, 683
- lumbosacral, in ankylosing spondylitis, 227
- thoracic, in DISH, 811
- Spondylarthropathy. *See also* Arthropathy
 HLA-B27, mesangial IgM nephropathy in, 1056
 seronegative, familial mediastinal fibrosis and, 221
- Sports injuries to soft tissue, 336
- Stanford Health Assessment Questionnaire, 1346
- Staphylococcus aureus* in septic arthritis, 1500
- Steinbrocker assessment, 1355
- Sternocostoclavicular hyperostosis, 784
- Steroid drugs. *See also* Corticosteroids; Glucocorticosteroids; Prednisolone; Prednisone
 giant cell arteritis and, 689
 intraarticular use, 1380
 polymyalgia rheumatica and, 689
 in RA, 937
 pulse therapy and, 1269
 in rabbit OA, 1132, 1380
 seizure after pulse therapy with methyl prednisolone, 117
 in SLE
 immune complexes and, 637
 natural killer cells and, 623
- Streptococcal cell wall-induced polyarthritis
 sex hormone effects on, in rats, 560
 in susceptible and resistant rats, 1442

- Subcutaneous fat necrosis, arthropathy and, in pancreatitis, 121
- Subcutaneous nodules
in gout in Heberden's nodes, 94
in pancreatitis, 121
in RA, 292
HLA antigens and, 1053
- Subluxation, lateral, of cervical spine in psoriatic arthritis, 109
- Sulphydryl, aspirin esterase of human erythrocyte and, 541
- Sulindac, 351
and DMSO in peripheral neuropathy, 791
for gout in Heberden's nodes, 1413
- Superoxide dismutase in rabbit OA, 1132, 1382, 1385
- Superoxide production, medullasin and, in inflammation, 1002
- Superoxide radical generation, gold compounds and, 82
- Suppressor cell index in PSS, 841
- Suppressor cells, 248. *See also* B cells; Helper cells; T cells
in neutropenia of Felty's syndrome, 947
in PSS, 841
in RA, after total lymphoid irradiation, 937
in SLE, 745
- Surface antigens, in gastric mucosa in Sjögren's syndrome, 1196
- Surgery
arthroscopic, 365
in RA, 301
- Symmetric polyarthritis, heterophile-negative infectious mononucleosis and, 553
- Synovectomy, radical, in lead arthropathy, 1048
- Synovia, vascular endothelium in, 1427
- Synovial biopsy
Lowe's (oculocerebrorenal) syndrome and, 728
in RA, 291
of vascular wall in PSS, 1042
- Synovial cells
cartilage destruction at cartilage-pannus junction and, 472
function, 764
human, proteoglycan synthesis in, 522
in Lowe's (oculocerebrorenal) syndrome, 728
mononuclear cell-stimulated, plasminogen activator and, 15
phenotypes, 1321
rheumatoid, 8
- Synovial complement system, immune complexes and, in RA, 156
- Synovial cyst, rheumatoid, of hip, 814
- Synovial effusions
corticosteroids and, 1283
Lowe's (oculocerebrorenal) syndrome and, 728
- Synovial fibroblasts, response to transforming growth factors, 1370
- Synovial fluid, 242
alizarin red S staining to detect calcium in, 191
antibodies to collagen in, 832
- Synovial fluid (*cont'd*)
Charcot-Leyden crystals in, 1416
in chronic monocytic arthritis, 674
fatty acids in pancreatitis, 121
IgM rheumatoid factor, rosette formation and, 1101
immune complexes in OA, 156
lactic acid in, 1499
in polyarthritis, 816
post intestinal bypass arthritis and, 680
in RA, 156, 290, 479
- Synovial membrane
in dog OA, 869
in rabbit OA, 881
rheumatoid, fibrin and fibronectin in, 479
- Synovial sheaths, tendon abnormalities in congenital camptodactyly and, 896
- Synovial tissue
cell phenotypes, 1321
in congenital camptodactyly, 896
RANA and EBV in RA, 712
- Synovial tumors, 286
- Synovitis
congenital familial, 896
crystal-induced, 1321
erosive, in hereditary amyloidosis, 1145
gout in Heberden's nodes and, 94
in juvenile arthritis, 1321
in polymyalgia rheumatica, 1417
in psoriasis, 1321
in RA, 1321
in seronegative polyarthritis, 1321
trauma-induced, 1321
- Synovium
in hereditary amyloidosis, 1145
hyaluronate synthesis and, 764
in lead arthropathy, 1048
in Lowe's (oculocerebrorenal) syndrome, 728
in rabbit OA, 883
- Syphilis mimicking OA, 1529
- Syphilitic arthritis, 265
- Systemic lupus erythematosus (SLE), 301. *See also* Central nervous system lupus; Cutaneous lupus; Discoid lupus; Drug-induced lupus; Lupus; Lupus diathesis; Lupus erythematosus; Lupus nephritis; Lupus screening questionnaire; Lupus-like syndrome; Neonatal lupus erythematosus; Polymyositis-systemic lupus erythematosus syndrome
age and, 45
antibodies to Sm and RNP and, 848
antibody/DNA complexes in, 736
antibody to DNA in, 45
anti-DNA antibodies and enzyme immunoassay in, 52
antidiuretic hormone in, 237, 1055
antilymphocytotoxic antibodies in, 570
antinuclear antibodies in, 45, 1104
anti-proliferating cell nuclear antigen and, 140

Systemic lupus erythematosus (*cont'd*)

- anti-SS-B antibodies and, 146
- arthritis in, 745
- autoantibodies in, 306
- beclomethasone dipropionate in, 1412
- cardiac involvement in, 304
- cellular immunity in, 307
- central nervous system in, 303
 - after pulse therapy, 809
- classification of, 1054
- clinical activity scoring of, 1317
- complement in, 45, 302, 309
 - enzyme immunoassay and, 52
- contraception in, 304
- corticosteroids in, 637
- disease activity and, 45
- environmental factors and, 309
- epidemiologic studies of, 391
- erythrocyte sedimentation rate and, 45
- erythrocytes in, 736
- experimental models of, 253, 310
- familial, in males, 39
- genetics and, 309
- with gout and Paget's disease of bone, 238
- granulocyte/monocyte progenitor cells in bone marrow in, 516
- granulopoiesis in, 516
- granulopoietic failure in, 516
- heart in, 304
- hematologic studies in, 303
- HLA haplotypes in, 1104
- HLA-DR, MB, and MT antigens in, 1533
- HNK-1⁺ lymphocytes in, 623
- hormone levels in, 1400
- human neutrophils in, 631
- hypertension in, 1340
- immune complexes and, 45, 308, 921
- interferon in, 575
 - function, 1452
 - lymphopenia and, 1415
- interleukin-2 production in, 1316
- K562 target cells in, 623
- kidney in, 302
- leukopenia in, 45
- lung in, 303
- lymphopenia in, 745
- morbidity in, intravascular aggregates and, 630
- murine model, hypertension in, 1340
- myocardial infarcts in, 1340
- natural killer cells in, 623, 1316, 1452
- neonatal, 304
- nephrotic syndrome associated with, 919
- neurofibromatosis in, 574
- neutrophil aggregation in, 630
- OKT3 antigen in, 623
- outcome in, 570

Systemic lupus erythematosus (*cont'd*)

- pancreatitis in, 238, 1173
- pathology of, 309
- platelet release reaction and, 179
- pregnancy and, 304
- proteinuria in, 918
- pulmonary involvement in, 303
- rash in, 745
- Reiter's syndrome and, 1405
- relatives of patients with, 921
- reproductive tract in, 304
- seroreactivity and, 45
- serotonin content of platelets in, 532
- steroid drugs and
 - immune complexes in, 637
 - natural killer cells in, 623
- synovial fluid lactic acid in, 1500
- synovial microvasculature in, 1427
- system involvement in, 47
- T cells in, 745, 932, 1399, 1479
- temporomandibular joint involvement in, 1506
- testosterone oxidation in, 1517
- thrombocytopenia in, 1181
- treatment of, 305
- in twins discordant for, 1400
- vascular disease in, 1340

Systemic lupus erythematosus-like symptoms in secondary syphilis, 1529

Systemic sclerosis, 312. *See also* Polymyositis-scleroderma;

Progressive systemic sclerosis; Scleroderma

- anticentromere antibodies in, 1
- antikeratin antibodies in, 494
- cancer and, 313
- capillary microscopy in eosinophilic fasciitis, 617
- nifedipine for pulmonary hypertension in, 794
- treatment of, 314
- vascular reactivity and pulmonary hypertension in, 1037

Systemic vasculitis, HLA antigens in, 102

T

T cell growth factor in joint fluid, 977

T cell subsets

- in polymyalgia rheumatica, 1472
- in RA after lymphoplasmapheresis, 1419
- in SLE, 745

T cells

- alpha-interferon and IgM rheumatoid factor in RA, 1091
- bone marrow, granulopoiesis in SLE and, 516
- fibroblast proliferation and, 22
- Ia antigens, articular cartilage and, 1187
- identification of, 1323, 1334
- IgM, rosette formation and, 1098
- in neutropenia of Felty's syndrome, 947
- in PSS, 841

- T cells (*cont'd*)
 in RA
 after methyl prednisolone, 231
 after total lymphoid irradiation, 937
 in SLE, 745, 1399
 isoenzymes of lactate dehydrogenase in, 932
 T lymphocytopenia in RA after total lymphoid irradiation, 937
 T_γ cells in PSS, 841
 T_m cells, rosette formation and, 1098
 Takayasu's arteritis, 322
 Tamoxifen in rabbit OA, 1132, 1380
 Tarsal tunnel syndrome, 337
^{99m}Tc methylene diphosphonate in axial skeleton in ankylosing spondylitis and Reiter's syndrome, 217
 joint scan in hereditary amyloidosis, 1145
 Temporal arteritis. *See* Giant cell arteritis
 Temporomandibular joint involvement in SLE, 1506
 Tendinitis, 335
 socioeconomic impact of, 901
 Tendons
 CPPD, vertebral hyperostosis and, in Barbary ape, 682
 in familial arthropathy and congenital camptodactyly, 896
 quadriceps, CPPD disease, vertebral hyperostosis and, in ape, 684
 Tenosynovitis, intrauterine, congenital camptodactyly and, 896
 Tenosynovium, abnormalities and diseases of, 896
 Tension headache in fibrositis, 817
 Testicular hyaluronidase
 articular cartilage, proteoglycans and, 1111
 indomethacin, glycosaminoglycan synthesis and, 528
 Testosterone in SLE, oxidation of, 1517
 Thalassemia. *See* Sickle cell-thalassemia
 Thoracic outlet syndrome, 337
 Thoracic spine in DISH, 811
 Thrombin-induced H-serotonin release, DNA and, 179
 Thrombocytopenia
 anti-proliferating cell nuclear antigen and, 140
 in SLE, 1181
 Thrombocytopenic purpura, idiopathic, familial SLE in males and, 39
 Thymidine incorporation, leukapheresis in RA and, 1076
 Tibial cartilage in rabbit OA, 875, 1137
 Tibial nerve palsy, anterior, after ankle arthrocentesis, 573
 Tibial plateau
 CPPD, vertebral hyperostosis and, in Barbary ape, 684
 human OA cartilage from, 63
 Ticlopidine in murine lupus, 1341
 Tight-skin mouse, 653
 "Tilt deformity" in OA, 909
 Tissue fat, synovial fluid fatty acids and, in pancreatitis, 121
 Tissue injury
 antibodies to collagen and, 832
 platelets and DNA at site of, 179
 Tolmetin, 350
 Tophaceous gout in sickle cell-thalassemia, 928
 Tophaceous nodules, ultrasound diagnosis of, 696
 Tophus in gout, 95, 98, 99
 Topical drugs in adjuvant arthritis, 861
 Total joint arthroplasty, 359
 Total knee arthroplasty, 362
 in juvenile arthritis, 1140
 Total lymphoid irradiation
 in psoriatic arthritis, 1052
 in RA, 937
 Total shoulder replacement, 364
 Toxicity
 D-penicillamine, 581
 gold, 1074
 in the elderly and, 705
 lead, 1057
 methotrexate, 119
 Tranexamic acid in rabbit OA, 1380
 Transferrin
 levels in RA, 1533
 plasma protein binding and, 775
 Transforming growth factors, synovial fibroblasts and, 1370
 Transmission electron microscopy in study of articular cartilage, 1115
 Trasylol in rabbit OA, 1382
 Trauma, "cocktail sausage" digit in, 664
 Traumatic arthritis
 hereditary chondrocalcinosis and, 1389
 interleukin-1-like factor in, 975
 synovial microvasculature in, 1427
 synovial tissue cells in, 1321
 Triamcinolone in rabbit OA, 1132, 1380
 Tribenocide in rabbit OA, 1132, 1380
 Triethylphosphine gold. *See also* Gold
 superoxide radical generation and, 82
 Tripeptide-activated polymorphonuclear leukocytes, 82
 Tritiated thymidine
 cytotoxicity in scleroderma and, 174
 incorporation in leukapheresis, 1076
 Trochanteric bursa, tuberculosis of, 77
 Trypsin
 cytotoxicity in scleroderma and, 170
 fibroblast proliferation and, 26
 immunoreactive, in pancreatitis, 121
 TSK mice, 653
 Tuberculosis of greater trochanteric bursa, 77
 Tumors, 286
 antibody/DNA complexes and erythrocytes in, 736
 Twins discordant for SLE, 1399
 Type II collagen-induced arthritis, 1120
- U**
- Ulcerations
 digital in scleroderma, 809
 esophageal, in Behçet's syndrome, 690

Ulcerations (*cont'd*)
 in Pond-Nuki dog OA, 866
 in rabbit OA, 875
 skin, wine treatment of in RA, 934
 Ulnar nerve entrapment, 337
 Ultrasound in diagnosis of nodules, 696
 Umbilical venous endothelial cells, cytotoxicity in scleroderma, 170
 Undifferentiated connective tissue disease. *See also* Connective tissue disease; Mixed connective tissue disease; Overlap syndrome
 antibodies to Sm and RNP in, 848
 Unproven treatments in arthritis, 1023
 Upper respiratory tract infections, Ig production in, 854
 Urate
 and hyperuricemia in gout, 1057
 renal handling of, 271
 Urate crystals
 acute gout and, 272
 gout in Heberden's nodes and, 95, 1413
 monosodium, plasma protein binding and, 775
 Urate-associated polypeptides, protein binding and, 777
 Uric acid
 measurement of, 270
 serum levels of, 87
 Uricosuric agents, 277
 Uronic acid
 aspirin and, in canine OA cartilage, 994
 in beagle OA, 72
 salicylates, glycosaminoglycan synthesis and, 528
 in skin of TSK mice, 653
 Urticaria, hypocomplementemic vasculitis and, 321

V

Vascular disease in murine lupus, 1340
 Vascular findings in Lowe's (oculocerebrorenal) syndrome, 728
 Vascular permeability, proteases and, 1008
 Vascular reactivity, pulmonary hypertension and, in systemic sclerosis, 1037
 Vasculitis, 319
 anti-(U1) RNP antibody in, 509
 systemic, HLA antigens in, 102

Vasodilators, cold stimuli and, in systemic sclerosis, 1037
 Venules, medullasin in granulocytes in inflammation and, 1002
 Vertebral ankylosis in hereditary chondrocalcinosis (correction), 112
 Vertebral hyperostosis concurrent with CPPD disease in Barbary ape, 682
 Video games implicated in interphalangeal region pain, 120
 Vimentin intermediate filaments, antikeratin antibodies in RA and, 494
 Viral arthritis, 264
 Vitamins in arthritis, 1023
 Vitreous deposits in hereditary amyloidosis, 1494

W

Walking time, D-penicillamine and, in RA, 581
 Water-fat in skin of TSK mice, 653
 Weather changes
 arthritis and, 1023
 hereditary chondrocalcinosis and, 1389
 Wegener's granulomatosis. *See also* Vasculitis
 HLA-DR2 antigen in, 102
 Whipple's disease, 328
 Wilson's disease, CPPD deposition and, 1387
 Wine treatment for rheumatoid skin ulcerations, 934
 Wrist
 in histoplasmosis, 1065
 M hominis septic arthritis in, 1044
 in pancreatic arthritis, 128

X-Z

X antigen in seronegative RA, 1412
Yersinia enterocolitica infection
 in chronic enteropathic arthritis, 1163
 Reiter's syndrome, HLA-B27, and, 1463
 Zinc levels in RA, 933, 1532
 Zomepirac, 1288